DK2277874T3 - ACTIVATOR FOR PEROXISOM PROLIFERATOR-ACTIVATED RECEPTOR - Google Patents

ACTIVATOR FOR PEROXISOM PROLIFERATOR-ACTIVATED RECEPTOR Download PDF

Info

Publication number
DK2277874T3
DK2277874T3 DK09731677.2T DK09731677T DK2277874T3 DK 2277874 T3 DK2277874 T3 DK 2277874T3 DK 09731677 T DK09731677 T DK 09731677T DK 2277874 T3 DK2277874 T3 DK 2277874T3
Authority
DK
Denmark
Prior art keywords
methyl
benzothiophen
trifluoromethyl
propionyl
ethyl
Prior art date
Application number
DK09731677.2T
Other languages
Danish (da)
Inventor
Shogo Sakuma
Rie Takahashi
Hideki Nakamura
Original Assignee
Nippon Chemiphar Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Chemiphar Co filed Critical Nippon Chemiphar Co
Application granted granted Critical
Publication of DK2277874T3 publication Critical patent/DK2277874T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A compound represented by the formula (I) or a pharmacologically acceptable salt thereof is used as an activator of PPAR. wherein each of R 1 and R 2 is hydrogen, C 1-8 alkyl, C 1-8 alkyl substituted with halogen, or the like; each of R 3 , R 4 , R 5 , and R 6 is hydrogen, C 1-8 alkyl, or the like; X is sulfur or the like; Y is oxygen, a bond, or the like; p is 0 or 1; A is oxygen, CH 2 , N-NH 2 , or the like; when p is 1, B is phenyl, which can have a substituent; when p is 0, B is a condensed ring such as benzisoxazole, which can have a substituent; m is an integer of 1 to 4; and n is an integer of 0 to 5.

Description

DESCRIPTION
Technical field [0001] The present invention relates to an activator of peroxisome proliferator activated receptor (PPAR).
Prior art [0002] As the activator of peroxisome proliferator activated receptor (PPAR), three subtypes, namely PPARa, PPAPy and ΡΡΑΡδ have been identified (Non-Patent document 1: Proc. Natl. Acad. Sci. USA, 91, p7335-7359, 1994).
[0003] Various compounds have been reported with respect to functions of activating transcription of the PPAR subtypes, lowering blood sugar level, or improving metabolism of lipid.
[0004] For example, WO 01/000603 (Patent Document 1) reports that GW-501516 (GSK) represented by the following formula has been developed as an agent for improving metabolism of lipid.
[0005] WO 2005/077926 (Patent Document 2) discloses the following compound, in which the thiazole ring of GW-501516 is replaced with a benzothiophene ring or a benzofuran ring.
[0006] The present inventors have found that the following compound disclosed in WO 2005/090920 (Patent Document 3) and the compounds disclosed in Patent Documents 4-10 have a function of activating transcription of PPAR.
Patent Document 4: WO 02/014291
Patent Document 5: WO 02/076957
Patent Document 6: WO 03/016291
Patent Document 7: WO 03/033493
Patent Document 8: WO 2007/004733
Patent Document 9: WO 2007/119887
Patent Document 10: WO 2008/016175 [0007] In the compound disclosed in Patent Document 2, the linker between the benzothiophene ring and the phenoxyacetic acid is an alkylene chain interrupted with sulfur or oxygen atom (X2), while the alkylene chain is not interrupted in the compound of the present invention as defined in the claims. In this regard, the compound of the present invention is distinct from the compound disclosed in Patent Document 2.
[0008] The linker in the compound of the present invention is also different from that of GW-501516 in the same manner as in the difference between the compound of the present invention and the compound disclosed in Patent Document 2. Further, the condensed ring, namely benzothiophene ring, contained in the compound of the present invention is replaced with the thiazole ring in GW-501516.
[0009] Turning to the compounds disclosed in Patent Documents 3-10, A in the compound disclosed in Patent Document 3 is a monocyclic ring such as pyrazole, thiophene, furan, pyrrole, while the compound of the present invention has a condensed ring, namely benzothiophene ring. The compounds disclosed in Patent Documents 4-10 also has a monocyclic ring corresponding to A of the compound disclosed in Patent Document 3.
[0010] As is described above, there are clear structural differences between the compound of the present invention and the above-mentioned compounds disclosed in the prior art documents.
Disclosure of invention [0011] The present invention provides a compound as defined in the claims or a pharmacologically acceptable salt thereof, which has a function of activating peroxisome proliferator activated receptor.
[0012] Disclosed herein is a compound having the following formula (I) or a pharmacologically acceptable salt thereof:
(I) wherein R1 is hydrogen, halogen, hydroxyl, nitro, amino, cyano, carboxyl, C-|_8 alkyl, cycloalkyl of three-membered to seven-membered ring, C2-8 alkenyl, C2-8 alkynyl, C-|_8 alkoxy, C-|_8 alkyl substituted with cycloalkyl of three-membered to seven-membered ring, C-|_8 alkyl substituted with halogen, C-|_8 alkyl substituted with C-|_8 alkoxy, C-|_8 alkoxy substituted with halogen, C2-8 acyl, C6-10 aryl, a heterocyclic group of five-membered or six-membered ring, aralkyl consisting of C6-10 aryl and C-|_8 alkylene, or C-|_8 alkyl substituted with a heterocyclic group of fivemembered or six-membered ring; R2 is hydrogen, C-|_8 alkyl, C2-8 alkenyl, C-|_8 alkyl substituted with cycloalkyl of three-membered to seven-membered ring, C-|_8 alkyl substituted with halogen, C-|_8 alkyl substituted with C-|_8 alkoxy, C2-8 acyl, Οθ-ΐο aryl, or aralkyl consisting of Οθ-ΐο aryl and C-|_8 alkylene; each of R3, R4, R5, and R6 independently is hydrogen, C-|_8 alkyl, or C-|_8 alkyl substituted with halogen; X is oxygen, sulfur, or NR7, wherein R7 is hydrogen, C-|_8 alkyl, C-|_8 alkyl substituted with halogen, aralkyl consisting of Οθ-ΐο aryl and C-|_8 alkylene, C2-8 acyl, or C2-8 alkenyl; Y is oxygen, sulfur, NR8, or a bond, wherein R8 is hydrogen, C-|_8 alkyl, C-|_8 alkyl substituted with halogen, C2-8 acyl, or C2-8 alkenyl; p is 0 or 1; A is oxygen, CH2, N-NH2, or N-OR9, wherein R9 is hydrogen, C-|_8 alkyl, C-|_8 alkyl substituted with halogen, C2-8 acyl, C2-8 alkenyl, or aralkyl consisting of Οθ-ΐο aryl and C-|_8 alkylene; when p is 1, B is phenyl, which can have a substituent selected from the group consisting of halogen, hydroxyl, nitro, amino, C-|_8 alkyl, cycloalkyl of three-membered to seven-membered ring, C2-8 alkenyl, C2-8 alkynyl, C-|_8 alkoxy, C-|_8 alkyl substituted with cycloalkyl of threemembered to seven-membered ring, C-|_8 alkyl substituted with halogen, C-|_8 alkyl substituted with C-|_8 alkoxy, C-|_8 alkoxy substituted with halogen, C2-8 acyl, Οθ-ΐο aryl, or aralkyl consisting of C6-10 aryl and C-pe alkylene; when p is 0, B is a condensed ring selected from the group consisting of indole, benzofuran,
benzisoxazole, or 1,2-benzisothiazole, each of which can have a substituent selected from the group consisting of halogen, hydroxyl, nitro, amino, C-|_8 alkyl, cycloalkyl of three-membered to seven-membered ring, C2-8 alkenyl, C2-8 alkynyl, C-|_8 alkoxy, C-|_8 alkyl substituted with cycloalkyl of three-membered to seven-membered ring, C-|_8 alkyl substituted with halogen, C-|. 8 alkyl substituted with C-|_8 alkoxy, C-|_8 alkoxy substituted with halogen, C2-8 acyl, Οθ-ΐο aryl, or aralkyl consisting of Οθ-ΐο aryl and C-|_8 alkylene, wherein Y binds to the benzene ring of B, and -(C(R3)(R4))m- binds to the condensed ring at the 3-position of B; m is an integer of 1 to 4; n is an integer of 0 to 5; and when n is 0, Y is a bond.
[0013] Also disclosed herein is a compound having the following formula (II) or a pharmacologically acceptable salt thereof:
(XI) wherein R11 is hydrogen, halogen, hydroxyl, nitro, amino, cyano, carboxyl, Ci_e alkyl, cycloalkyl of three-membered to seven-membered ring, C2-8 alkenyl, C2-8 alkynyl, C-|_8 alkoxy, C-|_8 alkyl substituted with cycloalkyl of three-membered to seven-membered ring, C-|_8 alkyl substituted with halogen, C-|_8 alkyl substituted with C-|_8 alkoxy, C-|_8 alkoxy substituted with halogen, C2-8 acyl, C6-10 aryl, a heterocyclic group of five-membered or six-membered ring, aralkyl consisting of C6-10 aryl and C-|_8 alkylene, or C-|_8 alkyl substituted with a heterocyclic group of fivemembered or six-membered ring; R12 is hydrogen, C-|_8 alkyl, C2-8 alkenyl, C-|_8 alkyl substituted with cycloalkyl of threemembered to seven-membered ring, C-|_8 alkyl substituted with halogen, C-|_8 alkyl substituted with C-i-8 alkoxy, C2-8 acyl, Οθ-ΐο aryl, or aralkyl consisting of Οθ-ΐο aryl and C-|_8 alkylene; each of R13, R14, R15, and R16 independently is hydrogen, C-|_8 alkyl, or C-|_8 alkyl substituted with halogen; Y1 is oxygen, sulfur, NR18, or a bond, wherein R18 is hydrogen, C-|_8 alkyl, C-|_8 alkyl substituted with halogen, C2-8 acyl, or C2-8 alkenyl; A1 is oxygen, CH2, N-NH2, or N-OR19, wherein R19 is hydrogen, C-|_8 alkyl, C-|_8 alkyl
substituted with halogen, C2-8 acyl, C2-8 alkenyl, or aralkyl consisting of Οθ-ΐο aryl and C-|_8 alkylene; Q1 is hydrogen, halogen, hydroxyl, nitro, amino, C-|_8 alkyl, cycloalkyl of three-membered to seven-membered ring, C2-8 alkenyl, C2-8 alkynyl, C-|_8 alkoxy, C-|_8 alkyl substituted with cycloalkyl of three-membered to seven-membered ring, C-|_8 alkyl substituted with halogen, C-|_ 8 alkyl substituted with C-|_8 alkoxy, C-|_8 alkoxy substituted with halogen, C2-8 acyl, Οθ-ΐο aryl, or aralkyl consisting of Οθ-ΐο aryl and C-|_8 alkylene; r is an integer of 1 to 4; and s is an integer of 1 to 5.
[0014] Also disclosed herein is a compound having the following formula (III) or a pharmacologically acceptable salt thereof:
(III) wherein R21 is hydrogen, halogen, hydroxyl, nitro, amino, cyano, carboxyl, C-|_8 alkyl, cycloalkyl of three-membered to seven-membered ring, C2-8 alkenyl, C2-8 alkynyl, C-|_8 alkoxy, C-|_8 alkyl substituted with cycloalkyl of three-membered to seven-membered ring, C-|_8 alkyl substituted with halogen, C-|_8 alkyl substituted with C-|_8 alkoxy, C-|_8 alkoxy substituted with halogen, C2-8 acyl, C6-10 aryl, a heterocyclic group of five-membered or six-membered ring, aralkyl consisting of C6-10 aryl and C-|_8 alkylene, or C-|_8 alkyl substituted with a heterocyclic group of fivemembered or six-membered ring; R22 is hydrogen, C-|_8 alkyl, C2-8 alkenyl, C-|_8 alkyl substituted with cycloalkyl of threemembered to seven-membered ring, C-|_8 alkyl substituted with halogen, C-|_8 alkyl substituted with C-|_8 alkoxy, C2-8 acyl, Οθ-ΐο aryl, or aralkyl consisting of Οθ-ΐο aryl and C-|_8 alkylene; each of R23, R24, R25, and R26 independently is hydrogen, C-|_8 alkyl, or C-|_8 alkyl substituted with halogen; Y2 is oxygen, sulfur, NR18, or a bond, wherein R28 is hydrogen, C-|_8 alkyl, C-|_8 alkyl substituted with halogen, C2-8 acyl, or C2-8 alkenyl; Q2 is hydrogen, halogen, hydroxyl, nitro, amino, C-|_8 alkyl, cycloalkyl of three-membered to seven-membered ring, C2-8 alkenyl, C2-8 alkynyl, C-|_8 alkoxy, C-|_8 alkyl substituted with cycloalkyl of three-membered to seven-membered ring, C-|_8 alkyl substituted with halogen, C-|_ 8 alkyl substituted with C-|_8 alkoxy, C-|_8 alkoxy substituted with halogen, C2-8 acyl, Οθ-ΐο aryl, or aralkyl consisting of Οθ-ΐο aryl and C-|_8 alkylene; t is an integer of 1 to 4; and u is an integer of 1 to 5.
[0015] The invention also relates to an activator of peroxisome proliferator activated receptor δ which contains as an effective component a compound as defined in the claims, or a pharmacologically acceptable salt thereof.
[0016] The invention further relates to a medicament for treatment and/or prophylaxis of a disease mediated by peroxisome proliferator activated receptor which contains as an effective component a compound as defined in the claims, or a pharmacologically acceptable salt thereof.
[0017] As disclosed in the formula (I), R1, R2, R3, R4, R5, R6, R7, R8, R9, and a substituent of phenyl or a condensed ring represented by B can be C-|_8 alkyl. Examples of the C-|_8 alkyl include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, and hexyl.
[0018] R1, R2, R7, R8, R9, and a substituent of phenyl or a condensed ring represented by B can be C2-8 alkenyl. Examples of the C2-8 alkenyl include vinyl and allyl.
[0019] R1 and a substituent of phenyl or a condensed ring represented by B can be C2-8 alkynyl. Examples of the C2-8 alkynyl include propargyl.
[0020] R1 and a substituent of phenyl or a condensed ring represented by B can be cycloalkyl of three-membered to seven-membered ring. Examples of the cycloalkyl of three-membered to seven-membered ring include cyclopropyl, cyclopentyl, and cyclohexyl.
[0021] R1 and a substituent of phenyl or a condensed ring represented by B can be C-|_8 alkoxy. Examples of the C-|_8 alkoxy include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, t-butoxy, pentyloxy, and hexyloxy.
[0022] R1 and a substituent of phenyl or a condensed ring represented by B can be halogen. Examples of the halogen include fluorine, chlorine, and bromine.
[0023] R1, R2, R3, R4, R5, R6, R7, R8, R9, and a substituent of phenyl or a condensed ring represented by B can be C-|_8 alkyl substituted with halogen. Examples of the C-|_8 alkyl substituted with halogen include methyl, ethyl, propyl, isopropyl, butyl, and t-butyl which are substituted with 1-3 halogens such as fluorine, chlorine, and bromine. Preferred are trifluoromethyl, chloromethyl, 2-chloroethyl, 2-bromoethyl, and 2-fluoroethyl.
[0024] R1, R2, and a substituent of phenyl or a condensed ring represented by B can be C-|_8 alkyl substituted with C-|_8 alkoxy. Examples of the C-|_8 alkyl substituted with C-|_8 alkoxy include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, and hexyl which are substituted with methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, t-butoxy, pentyloxy, or hexyloxy. Preferred is ethoxyethyl.
[0025] R1 and a substituent of phenyl or a condensed ring represented by B can be C-|_8 alkoxy substituted with halogen. Examples of the C-|_8 alkoxy substituted with halogen include methoxy, ethoxy, propoxy, isopropoxy, butoxy, and t-butoxy which are substituted with 1-3 halogen atoms such as fluorine atom, chlorine atom, or bromine atom. Preferred are trifluoromethoxy, chloromethoxy, 2-chloroethoxy, 2-bromoethoxy, and 2-fluoroethoxy.
[0026] R1, R2, and a substituent of phenyl or a condensed ring represented by B can be Οθ-ΐο aryl. Examples of the Οθ-ΐο aryl include phenyl.
[0027] R1, R2, R7, R8, R9, and a substituent of phenyl or a condensed ring represented by B can be C2-8 acyl. Examples of the C2-8 acyl include acetyl.
[0028] R1 and a substituent of phenyl or a condensed ring represented by B can be a fivemembered or six-membered heterocyclic group. Examples of the five-membered or sixmembered heterocyclic group include pyridyl.
[0029] R1, R2, and a substituent of phenyl or a condensed ring represented by B can be C-|_8 alkyl substituted with cycloalkyl of three-membered to seven-membered ring. Examples of the C-|_8 alkyl substituted with cycloalkyl of three-membered to seven-membered ring include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, and hexyl that are substituted with cyclopropyl, cyclopentyl, or cyclohexyl.
[0030] R1, R2, R7, R9, and a substituent of phenyl or a condensed ring represented by B can be aralkyl consisting of Οθ-ΐο aryl and C-|_8 alkylene. Examples of the aralkyl include benzyl and phenethyl.
[0031] R1 can be C-|_8 alkyl substituted with a heterocyclic group of five-membered or sixmembered ring. Examples of the C-|_8 alkyl substituted with a heterocyclic group of fivemembered or six-membered ring include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, and hexyl that are substituted with pyridyl.
[0032] R1 (except for hydrogen) and a substituent of phenyl or a condensed ring represented by B can be present as 1 to 3 groups, two of which can be different from each other.
[0033] R1 can also be dialkylamino. Examples of dialkylamino include dimethylamino and diethylamino. R2 can also be cycloalkyl of three-membered to seven-membered ring. Examples of the cycloalkyl of three-membered to seven-membered ring include cyclopropyl, cyclopentyl, and cyclohexyl.
[0034] R1 preferably is a group or an atom other than hydrogen, and R2 preferably is C2-6 alkyl.
[0035] As disclosed in the formula (II), R11, R12, R13, R14, R15, R16, R18, R19, and Q1 can be C-i-8 alkyl. Examples of the C-|_8 alkyl include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, and hexyl.
[0036] R11, R12, R18, R19, and Q1 can be C2-8 alkenyl. Examples of the C2-8 alkenyl include vinyl and allyl.
[0037] R11 and Q1 can be C2-8 alkynyl. Examples of the C2-8 alkynyl include propargyl.
[0038] R11 and Q1 can be cycloalkyl of three-membered to seven-membered ring. Examples of the cycloalkyl of three-membered to seven-membered ring include cyclopropyl, cyclopentyl, and cyclohexyl.
[0039] R11 and Q1 can be C-|_8 alkoxy. Examples of the C-|_8 alkoxy include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, t-butoxy, pentyloxy, and hexyloxy.
[0040] R11 and Q1 can be halogen. Examples of the halogen include fluorine, chlorine, and bromine.
[0041] R11, R12, R13, R14, R15, R16, R18, R19, and Q1 can be C^s alkyl substituted with halogen. Examples of the C-|_8 alkyl substituted with halogen include methyl, ethyl, propyl, isopropyl, butyl, and t-butyl that are substituted with 1-3 halogens such as fluorine, chlorine, and bromine. Preferred are trifluoromethyl, chloromethyl, 2-chloroethyl, 2-bromoethyl, and 2-fluoroethyl.
[0042] R11, R12, and Q1 can be C-|_8 alkyl substituted with C-|_8 alkoxy. Examples of the C-|_8 alkyl substituted with C-|_8 alkoxy include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, and hexyl which are substituted with methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, t-butoxy, pentyloxy, or hexyloxy. Preferred is ethoxyethyl.
[0043] R11 and Q1 can be C-|_8 alkoxy substituted with halogen. Examples of the C-|_8 alkoxy substituted with halogen include methoxy, ethoxy, propoxy, isopropoxy, butoxy, and t-butoxy that are substituted with 1-3 halogen atoms such as fluorine atom, chlorine atom, or bromine atom. Preferred are trifluoromethoxy, chloromethoxy, 2-chloroethoxy, 2-bromoethoxy, and 2-fluoroethoxy.
[0044] R11, R12, and Q1 can be Οθ-ΐο aryl. Examples of the Οθ-ΐο aryl include phenyl.
[0045] R11, R12, R18, R19, and Q1 can be C2-8 acyl. Examples of the C2-8 acyl include acetyl.
[0046] R11 can be a five-membered or six-membered heterocyclic group. Examples of the five-membered or six-membered heterocyclic group include pyridyl.
[0047] R11, R12, and Q1 can be C-|_8 alkyl substituted with cycloalkyl of three-membered to seven-membered ring. Examples of the C-|_8 alkyl substituted with cycloalkyl of threemembered to seven-membered ring include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, and hexyl that are substituted with cyclopropyl, cyclopentyl, or cyclohexyl.
[0048] R11, R12, R19, and Q1 can be aralkyl consisting of Οθ-ΐο aryl and C-|_8 alkylene.
Examples of the aralkyl include benzyl and phenethyl.
[0049] R11 can be C-|_8 alkyl substituted with a heterocyclic group of five-membered or sixmembered ring. Examples of the C-|_8 alkyl substituted with a heterocyclic group of fivemembered or six-membered ring include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, and hexyl that are substituted with pyridyl.
[0050] R11 (except for hydrogen) and Q1 can be present as 1 to 3 groups, two of which can be different from each other.
[0051] As disclosed in formula (III), R21, R22, R23, R24, R25, R26, R28, and Q2 can be C-|_8 alkyl. Examples of the C-|_8 alkyl include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, and hexyl.
[0052] R21, R22, R28, and Q2 can be C2-8 alkenyl. Examples of the C2-8 alkenyl include vinyl and allyl.
[0053] R21 and Q2 can be C2-8 alkynyl. Examples of the C2-8 alkynyl include propargyl.
[0054] R21 and Q2 can be cycloalkyl of three-membered to seven-membered ring. Examples of the cycloalkyl of three-membered to seven-membered ring include cyclopropyl, cyclopentyl, and cyclohexyl.
[0055] R21 and Q2 can be C-|_8 alkoxy. Examples of the C-|_8 alkoxy include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, t-butoxy, pentyloxy, and hexyloxy.
[0056] R21 and Q2 can be halogen. Examples of the halogen include fluorine, chlorine, and bromine.
[0057] R21, R22, R23, R24, R25, R26, R28, and Q2 can be C-|_8 alkyl substituted with halogen. Examples of the C-|_8 alkyl substituted with halogen include methyl, ethyl, propyl, isopropyl, butyl, and t-butyl that are substituted with 1-3 halogens such as fluorine, chlorine, and bromine. Preferred are trifluoromethyl, chloromethyl, 2-chloroethyl, 2-bromoethyl, and 2-fluoroethyl.
[0058] R21, R22, and Q2 can be C-|_8 alkyl substituted with C-|_8 alkoxy. Examples of the C-|_8 alkyl substituted with C-|_8 alkoxy include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, and hexyl which are substituted with methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, t-butoxy, pentyloxy, or hexyloxy. Preferred is ethoxyethyl.
[0059] R21 and Q2 can be C-|_8 alkoxy substituted with halogen. Examples of the C-|_8 alkoxy substituted with halogen include methoxy, ethoxy, propoxy, isopropoxy, butoxy, and t-butoxy that are substituted with 1-3 halogen atoms such as fluorine atom, chlorine atom, or bromine atom. Preferred are trifluoromethoxy, chloromethoxy, 2-chloroethoxy, 2-bromoethoxy, and 2-fluoroethoxy.
[0060] R21, R22, and Q2 can be Οθ-ΐο aryl. Examples of the Οθ-ΐο aryl include phenyl.
[0061] R21, R22, R28, and Q2 can be C2-8 acyl. Examples of the C2-8 acyl include acetyl.
[0062] R21 can be a five-membered or six-membered heterocyclic group. Examples of the five-membered or six-membered heterocyclic group include pyridyl.
[0063] R21, R22, and Q2 can be C-|_8 alkyl substituted with cycloalkyl of three-membered to seven-membered ring. Examples of the C-|_8 alkyl substituted with cycloalkyl of threemembered to seven-membered ring include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, and hexyl that are substituted with cyclopropyl, cyclopentyl, or cyclohexyl.
[0064] R21, R22, and Q2 can be aralkyl consisting of Οθ-ΐο aryl and C-|_8 alkylene. Examples of the aralkyl include benzyl and phenethyl.
[0065] R21 can be C-|_8 alkyl substituted with a heterocyclic group of five-membered or sixmembered ring. Examples of the C-|_8 alkyl substituted with a heterocyclic group of fivemembered or six-membered ring include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, and hexyl that are substituted with pyridyl.
[0066] R21 (except for hydrogen) and Q2 can be present as 1 to 3 groups, two of which can be different from each other.
[0067] Preferred compounds are shown below. 1. (1) A reference compound having the formula (II) or a pharmacologically acceptable salt thereof, wherein R11 is hydrogen, C-|_8 alkyl, or C-|_8 alkyl substituted with halogen. 2. (2) A reference compound having the formula (II) or a pharmacologically acceptable salt thereof, wherein R12 is C-|_8 alkyl or C-|_8 alkyl substituted with halogen. 3. (3) A reference compound having the formula (II) or a pharmacologically acceptable salt thereof, wherein each of R13 and R14 is hydrogen. 4. (4) A reference compound having the formula (II) or a pharmacologically acceptable salt thereof, wherein each of R15 and R16 independently is hydrogen or C-|_8 alkyl. 5. (5) A reference compound having the formula (II), or a pharmacologically acceptable salt thereof, wherein Y1 is oxygen, N(C-|_8 alkyl), or a bond. 6. (6) A reference compound having the formula (II) or a pharmacologically acceptable salt thereof, wherein A1 is oxygen, CH2, N-OH, or N-O-benzyl. 7. (7) A reference compound having the formula (II) or a pharmacologically acceptable salt thereof, wherein Q1 is C-|_8 alkyl or C-|_8 alkyl substituted with halogen. 8. (8) A reference compound having the formula (II) or a pharmacologically acceptable salt thereof, wherein r is 2. 9. (9) A reference compound having the formula (II) or a pharmacologically acceptable salt thereof, wherein s is 1 or 2. 10. (10) A reference compound having the formula (III) or a pharmacologically acceptable salt thereof, wherein R21 is hydrogen, C-|_8 alkyl, or C-|_8 alkyl substituted with halogen. 11. (11) A reference compound having the formula (III) or a pharmacologically acceptable salt thereof, wherein R22 is C-|_8 alkyl or C-|_8 alkyl substituted with halogen. 12. (12) A reference compound having the formula (III) or a pharmacologically acceptable salt thereof, wherein each of R23 and R24 is hydrogen. 13. (13) A reference compound or a pharmacologically acceptable salt thereof, wherein each of R25 and R26 independently is hydrogen or C-|_8 alkyl. 14. (14) A reference compound or a pharmacologically acceptable salt thereof, wherein Y2 is oxygen, N(C-|.s alkyl), or a bond. 15. (15) A reference ompound or a pharmacologically acceptable salt thereof, wherein Q2 is C-|_8 alkyl or C-|_8 alkyl substituted with halogen. 16. (16) A reference compound of formula (III) or a salt thereof, wherein t is 2. 17. (17) A reference compound of formula (III) or a pharmacologically acceptable salt thereof, wherein u is 1 or 2. 18. (18) A compound or a pharmacologically acceptable salt thereof of the present invention, wherein the compound is selected from the group consisting of 2-methyl-4-[3-(3-methylbenzothiophen-2-yl)propionyl]phenoxyacetic acid, 2-methyl-2-[2-methyl-4-[3-(3-methylbenzothiophen-2-yl)propionyl]phenoxy]propionic acid, 2-methyl-4-[3-[3-methyl-5-(trifluoromethyl)-benzothiophen-2-yl]propionyl]phenoxyacetic acid, 2-methyl-2-[2-methyl-4-[3-[3-methyl-5-(trifluoromethyl)-benzothiophen-2- yl]propionyl]phenoxy]propionic acid, 2-methyl-4-[3-[3-methyl-6- (trifluoromethyl)benzothiophen-2-yl]propionyl]phenoxyacetic acid, 2-methyl-2-[2-methyl-4-[3-[3-methyl-6-(trifluoromethyl)benzothiophen-2-yl]propionyl]phenoxy]propionic acid, 3- [4-[3-[3-methyl-6-(trifluoromethyl)benzothiophen-2-yl]propionyl]-2- methylphenyl]propionic acid, 3-[4-[3-[3-ethyl-6-(trifluoromethyl)benzothiophen-2-yl]propionyl]-2-methylphenyl]propionic acid, 3-[2-methyl-4-[3-[3-propyl-6- (trifluoromethyl)benzothiophen-2-yl]propionyl]phenyl]propionic acid, 3-[2-methyl-4-[3-[3-butyl-6-(trifluoromethyl)benzo-thiophen-2-yl]propionyl]phenyl]propionic acid, 3-[2-methyl- 4- [3-[3-isobutyl-6-(trifluoromethyl)benzothiophen-2-yl]propionyl]phenyl]propionic acid, 3-[2-methyl-4-[3-[3-isopropyl-6-(trifluoromethyl)benzothiophen-2- yl]propionyl]phenyl]propionic acid, 3-[4-[1-hydroxyimino-3-[3-isopropyl-6- (trifluoromethyl)benzothiophen-2-yl]propyl]-2-methylphenyl]propionic acid, 3-[4-[1-[2-[3-isopropyl-6-(trifluoromethyl)benzothiophen-2-yl]ethyl]vinyl]-2-methylphenyl]propionic acid, 4-[3-[3-isopropyl-6-(trifluoromethyl)benzothiophen-2-yl]propionyl]-2- methylphenoxyacetic acid, 4-[1-hydroxyimino-3-[3-isopropyl-6- (trifluoromethyl)benzothiophen-2-yl]propyl]-2-methylphenoxyacetic acid, 4-[3-[3-isopropyl-6-(trifluoromethyl)benzothiophen-2-yl]-1-methoxyiminopropyl]-2- methylphenoxyacetic acid, 4-[1-benzyloxyimino-3-[3-isopropyl-6- (trifluoromethyl)benzothiophen-2-yl]propyl]-2-methylphenoxyacetic acid, 5-hydroxy-2-methyl-4-[3-[3-propyl-6-(trifluoromethyl)benzothiophen-2-yl]propionyl]phenoxyacetic acid, and 5-hydroxy-4-[1-hydroxyimino-3-[3-propyl-6-(trifluoromethyl)benzothiophen-2-yl]propyl]-2-methylphenoxyacetic acid.
[0068] The compound having the formula (I), (II), or (III) can be present in the form of a pharmacologically acceptable salt. Examples of the salt include an alkali metal salt, such as sodium salt, potassium salt and lithium salt.
[0069] The compound of the present invention can also be present in the form of an optical isomer such as enantiomer or racemic body, or a geometrical isomer such as cis or trans. These isomers are included in the scope of the present invention.
[0070] The synthesis scheme for preparing the compound of the formula (I) or (II) are described below.
Synthetic process 1 (wherein Y is oxygen in the formula (I)) [0071]
[0072] In the formulas, Z1 is halogen such as bromine, R01 is a lower alkyl such as ethyl, and each of R1, R2, R3, R4, R5, R6, X, p, A, B, m, and n are described above. 1. (a) The ester of the formula (iii) can be obtained by a reaction of the compound of the formula (i) with the compound of the formula (ii) in the presence of a base such as potassium carbonate in an inert solvent such as acetone. 2. (b) The compound represented by the formula (iv) can be obtained by a reaction of the compound of the formula (iii) in the presence of lithium hydroxide in an inert solvent such as ethanol or methanol.
Synthetic process 2 (wherein the combination of Y and (C)n(R5)(R6) is ethylene in the formula (I)) [0073]
1) HBr, NaNQ,
[0074] In the formulas, R02 is a lower alkyl such as ethyl, and each of R1, R2, R3, R4, X, p, A, B, and m are described above. 1. (a) The compound of the formula (vi) can be obtained by subjecting the compound of the formula (v) to diazotization for example by using hydrobromic acid and sodium nitrite, and a reaction with an alkyl acrylate. 2. (b) The compound of the formula (vii) can be obtained by refluxing the compound of the formula (vi) while heating in the presence of a base such as triethylamine in an alcohol such as methanol. 3. (c) The compound of the formula (viii) can be obtained by subjecting the compound of the formula (vii) to a process analogous to the above-mentioned synthetic process 1(b). 4. (d) The compound represented by the formula (ix) can be obtained by reducing the compound of the formula (viii) using hydrazine hydrate.
[0075] Synthetic process 3 (wherein Y is NR8 in the formula (1))
[0076] In the formulas, Z2 is halogen such as bromine, R03 is a lower alkyl such as ethyl, and each of R1, R2, R3, R4, R5, R6, R8, X, p, A, B, m, and n are described above. 1. (a) The compound of the formula (xii) can be obtained by a reaction of the compound of the formula (x) with the compound of the formula (xi) in the presence of sodium hydride in a solvent such as DMF. 2. (b) The compound represented by the formula (xiii) can be obtained by subjecting the compound of the formula (xii) to a process analogous to the above-mentioned synthetic process 1(b).
Synthetic process 4 (wherein A1 is oxygen, and (C)r(R13)(R14) is ethylene in the formula (ll)) [0077]
[0078] In the formulas, R04 is a lower alkyl such as ethyl, and each of R11, R12, R15, R16, Y1, Q1, and s are described above. 1. (a) The compound of the formula (xvi) can be obtained by a reaction of the compound of the formula (xiv) with the compound of the formula (xv) in the presence of sodium methoxide in an inert solvent such as THF. 2. (b) The compound of the formula (xvii) can be obtained by subjecting the compound of the formula (xvi) to hydrogenation reduction in the presence of palladium-carbon. 3. (c) The compound represented by the formula (xviii) can be obtained by subjecting the compound of the formula (xvii) to a process analogous to the above-mentioned synthetic process 1(b).
Synthetic process 5 (wherein A1 is N-OH in the formula (II)) [0079]
[0080] In the formulas, R05 is a lower alkyl such as ethyl, and each of R11, R12, R13, R14, R15, R16, Y1, Q1, r, and s are described above. 1. (a) The compound of the formula (xx) can be obtained by a reaction of the compound of the formula (xix) with hydrochloric salt of hydroxylamine. 2. (b) The compound represented by the formula (xxi) can be obtained by subjecting the compound of the formula (xx) to a process analogous to the above-mentioned synthetic process 1(b).
Synthetic process 6 (wherein A1 is CH2 in the formula (II)) Γ00811
[0082] In the formulas, R06 is a lower alkyl such as ethyl, and each of R11, R12, R13, R14, R15, R16, Y1, Q1, r, and s are described above. 1. (a) The compound of the formula (xxiii) can be obtained by a reaction of the compound of the formula (xxii) with trimethylphosphonium bromide in the presence of sodium amide in a solvent such as THF. 2. (b) The compound represented by the formula (xxiv) can be obtained by subjecting the compound of the formula (xxiii) to a process analogous to the above-mentioned synthetic process 1(b).
[0083] The compounds of the formulas (I), (II), and (III) can be prepared referring to the above-mentioned synthetic processes, as well as the below-mentioned synthesis examples, and the synthesis examples described in the above-mentioned patent documents 1-10.
[0084] Examples of the compounds are shown below.
Representative compound 1 [0085]
[0086] In the formula, R11, R12, A1, Q1, Y1, R15, and R16 are set forth in Tables 1 to 3. TABLE 1
* = reference compounds TABLE 2
TABLE 3
Representative compound 2 [0087]
[0088] In the formula, R11, R12, A1, Q1, Y1, and s are set forth in Tables 4 to 6. * = reference compounds TABLE 4
TABLE 5
TABLE 6
Representative compound 3 (asreference) [0089]
[0090] In the formula, R11, R12, r, A1, Q1, Y1, R15, and R16 are set forth in Tables 7 and 8. TABLE 7
TABLE 8
Representative compound 4 (asreference) [0091]
[0092] In the formula, X, R1, R2, A, Q, Y, n, R5, and R6 are set forth in Tables 9 and 10.
TABLE 9
TABLE 10
Representative compound 5 (asreference) [0093]
[0094] In the formula, X, R1, R2, A, Q, Y, n, R5, and R6 are set forth in Tables 11 to 13. TABLE 11
TABLE 12
TABLE 13
Representative compound 6 (asreference) [0095]
[0096] In the formula, X, R1, R2, A, Q, Y, n, R5, and R6 are set forth in Tables 14 and 15. TABLE 14
TABLE 15
Representative compound 7 (asreference) [0097]
[0098] In the formula, X, R1, R2, A, Q, Y, s, R5, and R6 are set forth in Tables 16 and 17. TABLE 16
TABLE 17
Representative compound 8 (as reference) [0099]
[0100] In the formula, R21, R22, t, Q2, Y2, u, R25, and R26 are set forth in Tables 18 and 19. TABLE 18
TABLE 19
Representative compound 9 (as reference) [0101]
[0102] In the formula, X, R1, R2, Q, Y, u, R2, and R6 are set forth in Tables 20 and 21. TABLE 20
TABLE 21
Representative compound 10 (as reference) [0103]
[0104] In the formula, X, R1, R2, m, Q, Y, n, R5, and R6 are set forth in Tables 22 and 23. TABLE 22
TABLE 23
[0105] The compounds of the formulas (I), (II), and (III) can be prepared referring to the above-mentioned synthetic processes, as well as the processes of the below-mentioned Examples 1-21, and the processes described in the above-mentioned patent documents 1-4.
[0106] The pharmacological effects of the invention are described below.
[0107] The PPAR activating effect of the compound of the invention was determined by the following method: A receptor expression plasmid (pSG5-GAL4-hPPARa or y or δ (LBD)), a luciferase expression plasmid (pUC8-MH100x4-TK-Luc), and a β-galactosidase expression plasmid (pCMX-P-GAL) are transfected into CV-1 cells. After the gene transfer is conducted utilizing a transfection reagent (Lipofectamine 2000, Invitrogen), it is incubated for about 40 hours in the presence of a compound to be tested. The luciferase activity and β-GAL activity are measured on the soluble cells.
[0108] The luciferase activity is calibrated with the β-GAL activity. A relative ligand activity is calculated under the condition that the luciferase activity of the cells treated with GW-590735 (selective agonist for PPARa), Rosiglitazone (selective agonist for PPARy), or GW-501516 (selective agonist for PPAR5) is set to 100% to determine EC50 (Example 29).
[0109] As is evident from Table 24, the compounds of the invention show an excellent activating effect for PPAR5. As is also evident from Table 26, the compounds of the present invention described in Examples 22 and 23 have an excellent activating effect for PPAR5 (Example 31).
[0110] As is further evident from Table 25, the reference compounds described in Examples 19 and 21 show a high selectivity for PPAR5) compared with GW-501516 (Example 30).
[0111] As is described above, the compounds of the present invention have an excellent activating effect for PPAR5. Therefore, the compounds are expected to be used for treatment or prophylaxis of diseases, which include metabolic diseases such as diabetes, diseases to be treated with a hypoglycemic agent, syndrome X, obesity, hypercholesterolemia, and hyperlipoproteinemia, hyperlipidemia, arteriosclerosis, cardiac insufficiency, cardiomyopathy, non-alcoholic fatty hepatitis, diseases of cardiovascular system, bulimia, ischemic diseases, malignant tumors such as lung cancer, cancer of the breast, colon cancer, large intestine cancer, and ovary cancer, Alzheimer disease, and inflammatory diseases.
[0112] The compound of the invention can be administered to human beings by ordinary administration methods such as oral administration or parenteral administration.
[0113] The compound can be granulated in ordinary manners for the preparation of pharmaceuticals. For instance, the compound can be processed to give pellets, granule, powder, capsule, suspension, injection, and suppository.
[0114] For the preparation of these pharmaceuticals, ordinary additives such as vehicles, disintegrators, binders, lubricants, dyes, and diluents can be used. As the vehicles, lactose, D-mannitol, crystalline cellulose and glucose can be mentioned. Further, there can be mentioned starch and carboxymethylcellulose calcium (CMC-Ca) as the disintegrators, magnesium stearate and talc as the lubricants, and hydroxypropylcellulose (HPC), gelatin and polyvinylpyrrolidone (PVP) as the binders.
[0115] The compound of the invention can be administered to an adult generally in an amount of 0.1 mg to 100 mg a day by parenteral administration and 1 mg to 2,000 mg a day by oral administration. The dosage can be adjusted in consideration of age and conditions of the patient.
[0116] The invention is further described by the following examples.
Examples
Reference example 1 (1) Methyl 3-methylbenzothiophene-2-carboxylate [0117] To a suspension of 55% sodium hydride (390 mg, 9.69 mmol) in THF (7 ml_)-DMS0 (20 mL) was added methyl thioglycolate (0.64 ml) under N2 atmosphere. After ceasing of bubbling, the mixture was stirred for 15 minutes at room temperature, to which was added slowly a solution of 2-fluoroacetophenone (0.89 mL, 6.46 mmol) in DMSO(5 mL). The mixture was stirred at room temperature for 1 hour, diluted with water, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the residue was recrystallized from ethyl acetate/hexane to give the titled compound as a white crystal (533 mg, 36%). 1H NMR (CDCI3, 400MHz) : δ= 2.78(3H,s), 3.93(3H,s), 7.4-7.5(2H,m), 7.8-7.9(2H,m). (2) 3-Methylbenzothiophene-2-methanol [0118] To an ice-cold suspension of lithium aluminum hydride (103 mg, 2.72 mmol) in THF (4.4 mL) was added dropwise over 15 minutes under N2 atmosphere, a solution of the above-mentioned methyl 3-methylbenzothiophene-2-carboxylate (560 mg, 2.72 mmol) in THF (1 mL). The mixture was stirred under ice-cooling for 45 minutes, then at room temperature for 5 minutes, to which was added dropwise under ice-cooling saturated aqueous ammonium chloride solution. The mixture was filtered through a layer of Celite, washed with ethyl acetate. Combined organic layers were washed with saturated brine. After drying over anhydrous sodium sulfate, the solvent was removed under reduced pressure to give the titled compound as a white crystal (483 mg, yield 99%). 1H NMR (CDCI3, 400MHz) : δ= 1.79(1 H,t,J=6Hz), 2.39(3H,s), 4.91 (2H,d,J=6Hz), 7.3-7.4(2H,m), 7.67(1 H,dd,J=1 Hz,8Hz), 7.81 (1 H,dd,J=1 Hz,8Hz).
Example 1 2- Methyl-4-[3-(3-methylbenzothiophen-2-yl)propionyl]-phenoxyacetic acid (1) 1 -(4-Hydroxy-3-methylphenyl)-3-(3-methylbenzothiophen-2-yl)propan-1 -one [0119] To an ice-cold solution of 3-methylbenzothiophene-2-methanol [Reference example 1] (480 mg, 2.69 mmol) in benzene (10 mL) was added dropwise, a solution of thionyl chloride (0.24 mL, 3.2 mmol) in benzene (3.5 mL). The mixture was stirred at room temperature for 3 hour, and concentrated under reduced pressure to give 2-chloromethyl-3-methylbenzothiophene as a yellow oil (548 mg, yield >99%).
[0120] Then, to a suspension of 55% sodium hydride (123 mg, 3.07 mmol) in THF (18 mL) was added dropwise over 10 minutes under N2 atmosphere, a solution of ethyl 3-(4-benzyloxy- 3- methylphenyl)-3-oxopropionate (870 mg, 2.79 mmol) in THF (5 mL). After 20 minutes, to the resultant mixture was added dropwise over 10 minutes a solution of 2-chloromethyl-3-methylbenzothiophene (548 mg, 2.79 mmol) in THF (5 mL). The mixture was heated under reflux for 25 hours, cooled to room temperature, and concentrated under reduced pressure. The residue was heated in acetic acid (18 mL) and concentrated hydrochloric acid (4 mL) at 110 °C for 20 hours. The reaction mixture was cooled at room temperature, extracted with ethyl acetate. The organic layer was washed with water,saturated aqueous sodium bicarbonate solution, and saturated brine, successively. After drying over anhydrous sodium sulfate, the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate = 4/1), to give the titled compound as a yellow crystal (790 mg, yield 95%). 1H NMR (CDCI3, 400MHz) : δ= 2.27(3H,s), 2.35(3H,s), 3.31 (4H,s), 5.36(1 H,brs), 6.79(1 H,d,J=8Hz), 7.28(1 H,dd,J=1 Hz,8Hz), 7.34(1 H,dt,J=1 Hz,8Hz), 7.61 (1 H,d,J=8Hz), 7.7-7.8(3H,m). (2) Ethyl 2-methyl-4-[3-(3-methylbenzothiophen-2-yl)-propionyl]phenoxyacetate [0121] To an ice-cold suspension of the above-mentioned 1-(4-hydroxy-3-methylphenyl)-3-(3-methylbenzothiophen-2-yl)propan-1-one (200 mg, 0.644 mmol) and potassium carbonate (178 mg, 1.29 mmol) in acetone (6.4 ml.) was added slowly ethyl bromoacetate (0.14 mL, 1.3 mmol). The mixture was heated under reflux for 3 hours, to which was added saturated aqueous ammonium chloride solution, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate =5/1), to give the titled compound as a colorless oil (223 mg, yield 87%). 1H NMR (CDCI3, 400MHz) : δ= 1.29(3H,t,J=7Hz), 2.31 (3H,s), 2.35(3H,s), 3.31 (4H,s), 4.26(2H,q,J=7Hz), 4.70(2H,s), 6.70(1 H,d,J=8Hz), 7.28(1 H,dd,J=1 Hz,8Hz), 7.34(1 H,dd,J=1 Hz,8Hz), 7.61 (1 H,d,J=8Hz), 7.77(3H,m). (3) 2-Methyl-4-[3-(3-methylbenzothiophen-2-yl)propionyl] phenoxyacetic acid [0122] To a solution of ethyl 2-methyl-4-[3-(3-methylbenzothiophen-2- yl)propionyl]phenoxyacetate in ethanol (2 ml_)/water (1 mL) was added lithium hydroxide monohydrate (70 mg, 1.7 mmol). The mixture was heated under reflux for 1 hour, cooled at room temperature. After addition of ice, the resultant mixture was acidified with 1M hydrochloric acid, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the residue was recrystallized from ethyl acetate/hexane to give the titled compound as a pale yellow crystal (120 mg, 59%). FAB-MS(m/e):369(M+1) 1H NMR (CDCI3, 400MHz) : δ= 2.31(3H,s), 2.35(3H,s), 3.31(4H,s), 4.76(2H,s), 6.73(1 H,d,J=8Hz), 7.2-7.4(2H,m), 7.61 (1 H,d,J=8Hz), 7.75(1 H,d,J=8Hz), 7.7-7.9(2H,m).
Example 2 2-Methyl-2-[2-methyl-4-[3-(3-methylbenzothiophen-2-yl)propionyl]phenoxy]propionic acid (1) Ethyl 2-methyl-2-[2-methyl-4-[3-(3-methylbenzothiophen-2- yl)propionyl]phenoxy]propionate [0123] To an ice-cold suspension of 1-(4-hydroxy-3-methylphenyl)-3-(3-methylbenzothiophen-2-yl)propan-1-one [Example 1 (1)] (200 mg, 0.645 mmol) and potassium carbonate (445 mg, 3.22 mmol) in 2-butanone (6.4 ml.) was added slowly ethyl 2-bromo-2-methylpropionate (0.48 ml_, 3.2 mmol). The mixture was heated under reflux for 20 hours, to which was added saturated aqueous ammonium chloride solution, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate =7/1), to give the titled compound as a pale yellow oil (198 mg, yield 72%). 1H NMR (CDCI3, 400MHz) : δ= 1.21 (3H,t,J=7Hz), 1.64(6H,s), 2.25(3H,s), 2.35(3H,s), 3.30(4H,s), 4.22(2H,q,J=7Hz), 6.60(1 H,d,J=8Hz), 7.2-7.3(1 H,m), 7.34(1 H,dt,J=1 Hz,8Hz), 7.61 (1 H,d,J=8Hz), 7.70(1 H,dd,J=2Hz,8Hz), 7.75(1 H,d,J=8Hz), 7.79(1 H,d,J=2Hz). (2) 2-Methyl-2-[2-methyl-4-[3-(3-methylbenzothiophen-2-yl)propionyl]phenoxy]propionic acid [0124] The titled compound was prepared from the above-mentioned ethyl 2-methyl-2-[2-methyl-4-[3-(3-methylbenzothiophen-2-yl)propionyl]phenoxy]propionate (198 mg, 0.0466 mmol) in a procedure similar to that of Example 1 (3) as a pale yellow amorphous (87 mg, yield 47 %). FAB-MS(m/e):397(M+1) 1H NMR (CDCI3, 400MHz) : δ= 1.69(6H,s), 2.24(3H,s), 2.32(3H,s), 3.28(4H,m), 6.72(1 H,d,J=8Hz), 7.25(1 H,t,J=7Hz), 7.32(1 H,t,J=7Hz), 7.58(1 H,d,J=8Hz), 7.6-7.8(2H,m), 7.78(1 H,m).
Example 3 2-Methyl-4-[3-[3-methyl-5-(trifluoromethyl)-benzothiophen-2- yl]propionyl]phenoxyacetic acid (1) 1 -(4-Hydroxy-3-methylphenyl)-3-[3-methyl-5-(trifluoromethyl)benzothiophen-2-yl)propan-1-one [0125] The titled compound was prepared from the above-mentioned 3-methy-5-(trifluoromethyl)benzothiophen-2-ylmethanol [WO 2005077926] (930 mg, 3.78 mmol) in a procedure similar to that of Example 1 (1) as a brown crystal (400 mg, yield 31 %). 1H NMR (CDCI3, 400MHz) : δ= 2.28(3H,s), 2.40(3H,s), 3.33(4H,s), 5.18(1 H,br s), 6.80(1 H,d,J=8Hz), 7.49(1 H,d,J=8Hz), 7.75(1 H,d,J=8Hz), 7.79(1 H,s), 7.84(1 H,d,J=8Hz), 7.86(1 H,s). (2) Ethyl 2-methyl-4-[3-[3-methyl-5-(trifluoromethyl)-benzothiophen-2- yl]propionyl]phenoxyacetate [0126] The titled compound was prepared from the above-mentioned 1-(4-hydroxy-3-methylphenyl)-3-[3-methyl-5-(trifluoromethyl)benzothiophen-2-yl)propan-1-one (200 mg, 0.529 mmol) in a procedure similar to that of Example 1 (2) as a white crystal (217 mg, yield 88 %). 1H NMR (CDCI3, 400MHz) : δ= 1.29(3H,t,J=7Hz), 2.31 (3H,s), 2.39(3H,s), 3.33(4H,s), 4.26(2H,q,J=7Hz), 4.70(2H,s), 6.70(1 H,d,J=8Hz), 7.49(1 H,d,J=8Hz), 7.7-7.9(4H,m). (3) 2-Methyl-4-[3-[3-methyl-5-(trifluoromethyl)-benzothiophen-2-yl]propionyl]phenoxyacetic acid [0127] The titled compound was prepared from the above-mentioned ethyl 2-methyl-4-[3-[3-methy-5-(trifluoromethyl) benzothiophen-2-yl]propionyl]phenoxyacetate (217 mg, 0.467 mmol) in a procedure similar to that of Example 1 (3) as a white crystal (156 mg, yield 77 %). FAB-MS(m/e):437(M+1) 1H NMR (CDCI3, 400MHz) : δ= 2.31 (3H,s), 2.39(3H,s), 3.33(4H,s), 4.77(2H,s), 6.74(1 H,d,J=8Hz), 7.49(1 H,d,J=8Hz), 7.7-7.9(4H,m). IR(KBr,cm-1): 2954, 2923, 2800, 2592, 1772, 1745, 1670, 1649, 1601, 1576, 1508, 1456, 1436, 1434, 1421, 1383, 1350, 1325, 1300, 1257, 1227, 1201, 1173, 1136, 1132, 1070, 1063, 1016, 947, 895, 891,889, 872, 825, 808, 775, 677, 660.
Example 4 2-Methyl-2-[2-methyl-4-[3-[3-methyl-5-(trifluoromethyl)-benzothiophen-2- yl]propionyl]phenoxy]propionic acid (1) Ethyl 2-methyl-2-[2-methyl-4-[3-[3-methyl-5-(trifluoromethyl)benzothiophen-2-yl]propionyl]phenoxy]propionate [0128] The titled compound was prepared from the above-mentioned 1-(4-hydroxy-3-methylphenyl)-3-[3-methyl-5-(trifluoromethyl)benzothiophen-2-yl)propan-1-one [Example 3 (1)] (200 mg, 0.529mmol) in a procedure similar to that of Example 2 (1) as a pale yellow oil (211 mg, yield 81%). 1H NMR (CDCI3, 400MHz) : δ= 1.21 (3H,t,J=7Hz), 1.64(6H,s), 2.25(3H,s), 2.39(3H,s), 3.2-3.4(4H,m), 4.21 (2H,q,J=7Hz), 6.60(1 H,d,J=8Hz), 7.49(1 H,d,J=8Hz), 7.69(1 H,dd,J=2Hz,8Hz), 7.7-7.9(3H,m). (2) 2-Methyl-2-[2-methyl-4-[3-[3-methyl-5-(trifluoromethyl)benzothiophen-2-yl]propionyl]phenoxy]propionic acid [0129] The titled compound was prepared from the above-mentioned ethyl 2-methyl-2-[2-methyl-4-[3-[3-methyl-5-(trifluoromethyl)benzothiophen-2-yl]propionyl]phenoxy]-propionate (211 mg, 0.428mmol) in a procedure similar to that of Example 1 (3) as a pale yellow oil (162 mg, yield 81 %) . FAB-MS(m/e):465(M+1) 1H NMR (CDCI3, 400MHz) : δ= 1.68(6H,s), 2.25(3H,s), 2.38(3H,s), 3.32(4H,s), 6.73(1 H,d,J=8Hz), 7.48(1 H,dd,J=1 Hz,8Hz), 7.73(1 H,dd,J=2Hz,8Hz), 7.79(1 H,d,J=2Hz), 7.82(1 H,d,J=8Hz), 7.85(1 H,d,J=1 Hz).
Example 5 2- Methyl-4-[3-[3-methyl-6-(trifluoromethyl)-benzothiophen-2- yl]propionyl]phenoxyacetic acid (1) 1 -(4-Hydroxy-3-methylphenyl)-3-[3-methyl-6-(trifluoromethyl)benzothiophen-2- yl)propan-1-one [0130] The titled compound was prepared from the above-mentioned 3-methy-6-(trifluoromethyl)benzothiophen-2-ylmethanol [WO 2005077926] (906 mg, 3.68 mmol) and Ethyl 3- (4-benzyloxy-3-methylphenyl)-3-oxopropionate (1.14 g, 3.65 mmol) in a procedure similar to that of Example 1 (1) as a brown powder (680 mg, yield 49 %). 1H NMR (CDCI3, 400MHz) : δ= 2.27(3H,s), 2.38(3H,s), 3.33(4H,s), 5.27(1 H,br s), 6.80(1 H,d,J=8Hz), 7.57(1 H,d,J=8Hz), 7.69(1 H,d,J=8Hz), 7.7-7.9(2H,m), 8.02(1 H,s). (2) Ethyl 2-methyl-4-[3-[3-methyl-6-(trifluoromethyl)-benzothiophen-2- yl]propionyl]phenoxyacetate [0131] The titled compound was prepared from the above-mentioned 1- (4-hydroxy-3-methylphenyl)-3-[3-methyl-6-(trifluoromethyl)- benzothiophen-2-yl)propan-1-one (200 mg, 0.529 mmol)in a procedure similar to that of Example 1 (2) as a yellow brown crystal (214 mg, yield 87 %). 1H NMR (CDCI3, 400MHz) : δ= 1.30 (3H,t,J=7Hz), 2.32 (3H,s), 2.40 (3H,s), 3.34 (4H,s), 4.27(2H,q,J=7Hz), 4.71 (2H,s), 6.71 (1 H,d,J=8Hz), 7.58(1 H,d,J=8Hz), 7.70(1 H,d,J=8Hz), 7.7-7.8(2H,m), 8.03(1 H,s). (3) 2-Methyl-4-[3-[3-methyl-6-(trifluoromethyl)benzothiophen-2-yl]propionyl]phenoxyacetic acid [0132] The titled compound was prepared from the above-mentioned ethyl 2-methyl-4-[3-[3-methyl-6-(trifluoromethyl) benzothiophen-2-yl]propionyl]phenoxyacetate (214 mg, 0.461 mmol) in a procedure similar to that of Example 1 (3) as a white crystal (146 mg, yield 73 %). FAB-MS(m/e):437(M+1) 1H NMR (CDCI3, 400MHz) : δ= 2.31 (3H,s), 2.39(3H,s), 3.34(4H,s), 4.77(2H,s), 6.74(1 H,d,J=8Hz), 7.56(1 H,dd,J=1 Hz,8Hz), 7.69(1 H,d,J=8Hz), 7.7-7.9(2H,m), 8.02(1 H,s). IR(KBr,cm-1): 2913, 2592, 1772, 1745, 1676, 1643, 1601, 1578, 1506, 1425, 1421, 1408, 1385, 1352, 1331, 1277, 1257, 1203, 1161, 1130, 1114, 1099, 1080, 887, 871,823, 815, 721.
Example 6 2-Methyl-2-[2-methyl-4-[3-[3-methyl-6-(trifluoromethyl)-benzothiophen-2-yl]propionyl]-phenoxy]propionic acid (1) Ethyl 2-methyl-2-[2-methyl-4-[3-[3-methyl-6-(trifluoromethyl)benzothiophen-2-yl]propionyl]phenoxy]propionate [0133] The titled compound was prepared from the above-mentioned 1-(4-hydroxy-3-methylphenyl)-3-[3-methyl-6-(trifluoromethyl)benzothiophen-2-yl)propan-1-one [Example 5 (1)] (200 mg, 0.529 mmol) in a procedure similar to that of Example 2 (1) as a pale yellow oil (252 mg, yield 97 %). 1H NMR (CDCI3, 400MHz) : δ= 1.21 (3H,t,J=7Hz), 1.65(6H,s), 2.25(3H,s), 2.38(3H,s), 3.3-3.4(4H,m), 4.22(2H,q,J=7Hz), 6.60(1 H,d,J=8Hz), 7.56(1 H,d,J=8Hz), 7.6-7.8(2H,m), 7.78(1 H,s), 8.01 (1 H,s). (2) 2-Methyl-2-[2-methyl-4-[3-[3-methyl-6-(trifluoromethyl)benzothiophen-2- yl]propionyl]phenoxy]propionic acid [0134] The titled compound was prepared from the above-mentioned ethyl 2-methyl-2-[2-methyl-4-[3-[3-methyl-6-(trifluoromethyl) benzothiophen-2-yl]propionyl]phenoxy]propionate (252 mg, 0.512 mmol) in a procedure similar to that of Example 1 (3) as a white crystal (170 mg, yield 72 %). FAB-MS(m/e):465(M+1) 1H NMR (CDCI3, 400MHz) : δ= 1.68(6H,s), 2.27(3H,s), 2.38(3H,s), 3.33(4H,s), 6.75(1 H,d,J=8Hz), 7.56(1 H,dd,J=1 Hz,8Hz), 7.68(1 H,d,J=8Hz), 7.73(1 H,dd,J=2Hz,8Hz), 7.81 (1 H,d,J=2Hz), 8.01 (1 H,s). IR(KBr,cm-1): 3072, 2997, 2927, 2563, 1712, 1672, 1603, 1581, 1502, 1413, 1406, 1385, 1352, 1323, 1279, 1257, 1159, 1120, 813.
Example 7 3-[4-[3-[3-Methyl-6-(trifluoromethyl)-benzothiophen-2-yl]propionyl]-2- methylphenyljpropionic acid (1) Methyl 3-[4-[3-[3-methyl-6-(trifluoromethyl)benzothiophen-2-yl]propenoyl]-2-methylphenyljacrylate [0135] To an ice-cold suspension of methyl (4-acetyl-2-methylphenyl)acrylate [WO 2007119887] (89 mg, 0.41 mmol) and powdered Molecular sieves 3A (250 mg) in THF (2 ml.) was added 0.5M MeONa in MeOH (1.0 mL, 0.49 mmol) under N2 atmosphere. The mixture was stirred for 10 minutes under ice-cooling, to which was added slowly a solution of 3-methyl-6-(trifluoromethyl)benzothiophen-2-carboxaldehyde (100 mg, 0.410 mmol) in THF (1.7 mL). The mixture was stirred for 4 hours under ice-cooling, neutralized with 1N hydrochloric acid, and filtered. The filtrate was washed with water, and the organic layer was dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the residue was recrystallized from ethyl acetate/hexane to give the titled compound as a yellow crystal (87 mg, 48%). 1H NMR (CDCI3, 400MHz) : δ= 2.55(3H,s), 2.61(3H,s), 3.84(3H,s), 6.47(1 H,d,J=16Hz), 7.42(1 H,d,J=15Hz), 7.62(1 H,d,J=8Hz), 7.68(1 H,d,J=8Hz), 7.83(1 H,d,J=8Hz), 7.8-7.9(2H,m), 7.99(1 H,d,J=16Hz), 8.08(1 H,s), 8.21 (1 H,d,J=15Hz). (2) Methyl 3-[4-[3-[3-methyl-6-(trifluoromethyl)benzothiophen-2-yl]propionyl]-2-methylphenyl]propionate [0136] Methyl 3-[4-[3-[3-methyl-6-(trifluoromethyl)benzothiophen-2-yl]propenoyl]-2- methylphenyl]acrylate (85 mg, 0.19 mmol) was hydrogenated in MeOH (1 ml_)/THF (1 ml.) for 1 hour at room temperature using 10% palladium-carbon (17 mg) as a catalyst. After removal of the catalyst by filtration, the filtrate was concentrated to dryness. The residue was purified by silica gel column chromatography (hexane/ethyl acetate =5/1), to give the titled compound as a pale yellow crystal (38 mg, yield 44%). 1H NMR (CDCI3, 400MHz) : δ= 2.37(3H,s), 2.39(3H,s), 2.60(2H,t,J=8Hz), 2.98(2H,t,J=8Hz), 3.35(4H,s), 3.68(3H,s), 7.22(1 H,d,J=8Hz), 7.57(1 H,d,J=8Hz), 7.68(1 H,s), 7.71 (1 H,d,J=8Hz), 7.7-7.8(1 H,m), 8.02(1 H,s). (3) 3-[4-[3-[3-Methyl-6-(trifluoromethyl)benzothiophen-2-yl]-propionyl]-2-methylphenyljpropionic acid [0137] The titled compound was prepared from the above-mentioned methyl 3-[4-[3-[3-methyl-6-(trifluoromethyl)-benzothiophen-2-yl]propionyl]-2-methylphenyl]propionate (38 mg, 0.085 mmol) in a procedure similar to that of Example 1 (3) as a white crystal (24 mg, yield 65 %). FAB-MS(m/e):435(M+1) 1H NMR (CDCI3, 400MHz) : δ= 2.37(3H,s), 2.39(3H,s), 2.66(2H,t,J=8Hz), 2.99(2H,t,J=8Hz), 3.35(4H,s), 7.24(1 H,d,J=8Hz), 7.57(1 H,d,J=8Hz),7.69(1 H,d,J=8Hz), 7.74(1 H,d,J=8Hz), 7.75(1 H,s), 8.02(1 H,s). IR(KBr,cm-1): 3419, 3180, 2916, 2661, 1722, 1662, 1604, 1570, 1456, 1413, 1408, 1354, 1327, 1259, 1230, 1157, 1112, 1082, 1068, 1066, 962, 879, 827, 771,721,644, 605.
Example 8 3-[4-[3-[3-Ethyl-6-(trifluoromethyl)benzothiophen-2-yl]propionyl]-2- methylphenyljpropionic acid (1) Methyl 3-[4-[3-[3-ethyl-6-(trifluoromethyl)benzothiophen-2-yl]propenoyl]-2-methylphenyl]acrylate [0138] The titled compound was prepared from 3-ethy-6-(trifluoromethyl)benzothiophen-2-carboxaldehyde [WO 2005077926] (185 mg, 0.716 mmol) and methyl 3-(4-acetyl-2-methylphenyl)acrylate (156 mg, 0.715 mmol)in a procedure similar to that of Example 7 (1) as a yellow crystal (186 mg, yield 57 %). 1H NMR (CDCI3, 400MHz) : δ= 1.31 (3H,t,J=7Hz), 2.55(3H,s), 3.09(2H,q,J=7Hz), 3.84(3H,s), 6.47(1 H,d,J=16Hz), 7.43(1 H,d,J=15Hz), 7.62(1 H,d,J=8Hz), 7.69(1 H,d,J=8Hz), 7.8-7.9(3H,m), 8.00(1 H,d,J=16Hz), 8.08(1 H,s), 8.20(1 H,d,J=15Hz). (2) Methyl 3-[4-[3-[3-methyl-6-(trifluoromethyl)benzothiophen-2-yl]propionyl]-2-methylphenyl]propionate [0139] The titled compound was prepared from the above-mentioned methyl 3-[4-[3-[3-ethyl-6-(trifluoromethyl)-benzothiophen-2-yl]propenoyl]-2-methylphenyl]acrylate (186 mg, 0.406 mmol) in a procedure similar to that of Example 7 (2) as a pale yellow crystal (100 mg, yield 53 %) 1H NMR (CDCI3,400MHz): δ= 1.24(3H,t,J=7Hz), 2.37(3H,s), 2.60(2H,t,J=8Hz), 2.88(2H,q,J=7Hz), 2.99(2H,t,J=8Hz), 3.36(4H, s), 3.68(3H,s), 7.23(1 H,d,J=8Hz), 7.56(1 H,d,J=8Hz), 7.7-7.8(3H,m), 8.03(1 H,s). (3) 3-[4-[3-[3-Ethyl-6-(trifluoromethyl)benzothiophen-2-yl]-propionyl]-2-methylphenyljpropionic acid [0140] The titled compound was prepared from the above-mentioned methyl 3-[4-[3-[3-ethyl-6-(trifluoromethyl)benzothiophen-2-yl]propionyl]-2-methylphenyl]propionate (100 mg, 0.216 mmol) in a procedure similar to that of Example 1 (5) as a pale yellow crystal (55 mg, yield 57 %) FAB-MS(m/e):449(M+1) 1H NMR (CDCI3,400MHz):5= 1.24(3H,t,J=7Hz), 2.38(3H,s), 2.67(2H,t,J=7Hz), 2.88(2H,q,J=7Hz), 3.00(2H,t,J=7Hz), 3.36(4H, s), 7.25(1 H,d,J=7Hz), 7.56(1 H,d,J=7Hz), 7.7-7.8(3H, m), 8.03(1 H,s). IR(KBr,cm-1): 3035, 2968, 2929, 2634, 1709, 1682, 1608, 1436, 1429, 1409, 1363, 1328, 1280, 1259, 1223, 1219, 1159, 1115, 1081, 1053, 883, 815.
Example 9 3-[2-Methyl-4-[3-[3-propyl-6-(trifluoromethyl)benzothiophen-2- yl]propionyl]phenyl]propionic acid (1) 1 -[2-Fluoro-4-(trifluoromethyl)phenyl]butan-1 -one [0141] To a solution of 1-bromo-2-fluoro-4-(trifluoromethyl)benzene (0.30ml_, 2.1 mmol) in THF (6ml_) was added dropwise 1.5M butyllithium in THF (1.65 ml.) at -78°C. The mixture was stirred at -78°C for 15 minutes, to which was added a solution of butyraldehyde (0.18 ml_, 2.5 mmol) in THF (2 ml) at -78°C. After stirring at -78°C for 30 minutes, the mixture was treated with acetic acid (1 ml_)/THF (2 mL), and then followed by water at room temperature. The organic layer was separated, and the aqueous layer was extracted with ether. The combined organic layers were washed with saturated brine. After drying over anhydrous sodium sulfate, the solvent was removed under reduced pressure to give 1-[2-fluoro-4-(trifluoromethyl)-phenyl]butanol. To a suspension of the product and powdered Molecular sieves 3A(750 mg) in dichloromethane was added pyridinium chlorochromate (887 mg, 4.12mmol). The mixture was stirred for 16 hours at room temperature, to which was added ether (20 mL) and silica gel (Wakogel C-300HG, 2 g). The mixture was stirred for 10 minutes at room temperature, and filtered. The filtrate was concentrated to dryness, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate = 6/1), to give the titled compound as a white crystal (323 mg, yield 67 %). 1H NMR (CDCI3, 400MHz): δ= 1.00(3H,t,J=7Hz), 1.7-1,8(2H,m), 2.97(2H,t,J=7Hz), 7.42(1 H,d,J=10Hz), 7.49(1 H,d,J=8Hz), 7.95(1 H,t,J=8Hz). (2) Methyl 3-propyl-6-(trifluoromethyl)benzothiophen-2-carboxylate [0142] The titled compound was prepared from the above-mentioned 1-[2-fluoro-4-(trifluoromethyl)phenyl]butan-1-one (320 mg, 1.37 mmol) in a procedure similar to that of Reference example 1 (1) as a colorless oil (230 mg, yield 56 %). 1H NMR (CDCI3, 400ΜΗζ):δ= 1.03(3H,t,J=7Hz), 1.71(2H,m), 3.2-3.4(2H,m), 3.95(3H,s), 7.63(1 H,d,J=8Hz), 7.95(1 H,d,J=8Hz), .12(1 H,s). (3) [3-Propyl-6-(trifluoromethyl)benzothiophen-2-yl]-methanol [0143] The titled compound was prepared from the above-mentioned methyl 3-propyl-6-(trifluoromethyl)benzothiophene-2-carboxylate (230 mg, 0.761 mmol) in a procedure similar to that of Reference example 1 (2) (126 mg, yield 60 %). 1H NMR (CDCI3,400MHz):0= 0.98(3H,t,J=7Hz), 1.6-1,7(2H,m), 1.89(1 H,t,J=6Hz), 2.84(2H,t,J=7Hz), 4.96(2H,d,J=6Hz), 7.58(1 H,dd,J=1 Hz,8Hz), 7.77(1 H,d,J=8Hz), 8.10(1 H,s). (4) 3-Propyl-6-(trifluoromethyl)benzothiophene-2-carboxaldehyde [0144] To a suspension of [3-propyl-6-(trifluoromethyl)-benzothiophen-2-yl]methanol (126 mg, 0.459 mmol) and powdered Molecular sieves 3A (250 mg) in dichloromethane (2.3 ml.) was added pyridinium chlorochromate (198 mg, 0.919 mmol). The mixture was stirred for 40 minutes at room temperature, to which was added ether (20 ml.) and silica gel (Wakogel C-300HG, 2 g). The mixture was stirred for 10 minutes at room temperature, and filtered. The filtered cake was washed out with ether. The filtrate and washings were combined, and concentrated to give the titled compound as a brown crystal (112 mg, yield 90 %). 1H NMR (CDCI3,400MHz):5= 1.04(3H,t,J=7Hz), 1.7-1,9(2H,m), 3.26(2H,t,J=7Hz), 7.65(1 H,d,J=8Hz), 8.01 (1 H,d,J=8Hz), 8.17(1H,s), 10.34(1H,s). (5) Methyl 3-[2-methyl-4-[3-[3-propyl-6-(trifluoromethyl)benzothiophen-2- yl]propenoyl]phenyl]acrylate [0145] The titled compound was prepared from the above-mentioned 3-propyl-6-(trifluoromethyl)benzothiophen-2-carboxaldehyde (112 mg, 0.411 mmol) and methyl 3-(4-acetyl-2-methylphenyl) acrylate (90 mg, 0.41 mmol) in a procedure similar to that of Example 7 (1) as a yellow crystall (107 mg, yield 55 %). 1H NMR (CDCI3,400MHz):5= 1.01 (3H,t,J=7Hz), 1.6-1.8(2H,m), 2.55(3H,s), 3.04 (2H,t,J=7Hz), 3.84(3H,s), 6.47(1 H,d,J=16Hz), 7.42(1 H,d,J=15Hz), 7.61 (1 H,d,J=8Hz), 7.69(1 H,d,J=8Hz), 7.85(1 H,d,J=8Hz), 7.8-7.9(2H,m), 8.00(1 H,d,J=16Hz), 8.08(1 H,s), 8.18(1 H,d,J=15Hz). (6) Methyl 3-[2-methyl-4-[3-[3-propyl-6-(trifluoromethyl)benzothiophen-2- yl]propionyl]phenyl]propionate [0146] The titled compound was prepared from the above-mentioned methyl 3-[2-methyl-4-[3-[3-propyl-6-(trifluoromethyl)benzothiophen-2-yl]propenoyl]phenyl]acrylate (85 mg, 0.18 mmol) in a procedure similar to that of Example 7 (2) as a colorless oil (22 mg, yield 20 %). 1H NMR (CDCI3,400MHz): δ= 1.00(3H,t,J=7Hz), 1.6-1.7(2H,m), 2.37(3H,s), 2.61 (2H,t,J=7Hz), 2.83(2H,t,J=7Hz), 2.99(2H,t,J=7Hz), 3.36(4H,s), 3.68(3H,s), 7.23(1 H,d,J=8Hz), 7.55(1 H,d,J=8Hz), 7.7-7.8(3H,m), 8.02(1 H,s). (7) 3-[2-Methyl-4-[3-[3-propyl-6-(trifluoromethyl)benzo-thiophen-2- yl]propionyl]phenyl]propionic acid [0147] The titled compound was prepared from the above-mentioned methyl 3-[2-methyl-4-[3-[3-propyl-6-(trifluoromethyl)benzothiophen-2-yl]propionyl]phenyl]propionate (38 mg, 0.08 mmol) in a procedure similar to that of Example 7 (3) as a white crystal (14 mg, yield 66 %). FAB-MS(m/e):463(M+1) 1H NMR (CDCI3,400MHz):5= 1.00(3H,t,J=7Hz), 1.6-1.7(2H,m), 2.38(3H,s), 2.67(2H,t,J=8Hz), 2.84(2H,t,J=8Hz), 3.00(2H,t,J=8Hz), 3.3-3.4(4H,m), 7.25(1 H,d,J=7Hz), 7.55(1 H,dd,J=2Hz,8Hz), 7.7-7.8(3H,m), 8.02(1 H,s). IR(KBr,cm-1): 2964, 2927, 1712, 1693, 1683, 1608, 1428, 1409, 1365, 1330, 1305, 1276, 1259, 1220, 1159, 1114, 1081,883, 817, 721,433, 422.
Example 10 3-[2-Methyl-4-[3-[3-butyl-6-(trifluoromethyl)benzothiophen-2- yl]propionyl]phenyl]propionic acid (1) 1 -[2-Fluoro-4-(trifluoromethyl)phenyl]pentan-1 -one [0148] The titled compound was prepared from 1-bromo-2-fluoro-4- (trifluoromethyl)benzene (200 mg, 0.823 mmol) and valeraldehyde (0.05 ml_, 0.8 mmol) in a procedure similar to that of Example 9 (1) as a pale yellow oil (114 mg, yield 97%). 1H NMR (CDCI3,400MHz):5= 0.95(3H,t,J=7Hz), 1.3-1,5(2H,m), 1.6-1,8(2H,m), 2.99(2H,td,J=3Hz,7Hz), 7.42(1 H,d,J=10Hz), 7.49(1 H,d,J=8Hz), 7.94(1 H,t,J=8Hz). (2) Methyl 3-butyl-6-(trifluoromethyl)benzothiophen-2-carboxylate [0149] The titled compound was prepared from the above-mentioned 1-[2-fluoro-4-(trifluoromethyl)phenyl]pentan-1-one (246 mg, 1.05 mmol) in a procedure similar to that of Example 1 (1) as a pale yellow oil (241 mg, yield 38 %). 1H NMR (CDCI3,400MHz):0= 0.97(3H,t,J=7Hz), 1.4-1,5(2H,m), 1.6-1,7(2H,m), 3.31 (2H,t,J=7Hz), 3.95(3H,s), 7.63(1 H,d,J=8Hz), 7.95(1 H,d,J=8Hz), 8.12(1 H,s). (3) [3-Butyl-6-(trifluoromethyl)benzothiophen-2-yl]-methanol [0150] The titled compound was prepared from the above-mentioned methyl 3-butyl-6-(trifluoromethyl)benzothiophen-2-carboxylate (240 mg, 0.759 mmol) in a procedure similar to that of Example 1 (2) (100 mg, yield 46 %). 1H NMR (CDCI3,400MHz):5= 0.95(3H,t,J=8Hz), 1.3-1,5(2H,m), 1.5-1,7(2H,m), 1.88(1 H,t,J=5Hz), 2.86(2H,t,J=8Hz), 4.96(2H,d,J=5Hz), 7.58(1 H,dd,J=1 Hz,8Hz), 7.77(1 H,d,J=8Hz), 8.10(1 H,s). (4) 3-Butyl-6-(trifluoromethyl)benzothiophene-2-carboxaldehyde [0151] The titled compound was prepared from the above-mentioned [3-butyl-6-(trifluoromethyl)benzothiophen-2-yl]methanol (100 mg, 0.347 mmol) in a procedure similar to that of Example 9 (4) as a pale brown oil (88 mg, yield 89 %). 1H NMR (CDCI3, 400MHz): δ= 0.97(3H,t,J=7Hz), 1.4-1,5(2H,m), 1.7-1,8(2H,m), 3.28(2H,t,J=7Hz), 7.65(1 H,d,J=8Hz), 8.01 (1 H,d,J=8Hz), 8.17(1H,s), 10.34(1H,s). (5) Methyl 3-[4-[3-[3-butyl-6-(trifluoromethyl)benzothiophen-2-yl]propenoyl]-2-methylphenyljacrylate [0152] The titled compound was prepared from the above-mentioned 3-butyl-6-(trifluoromethyl)benzothiophen-2-carboxaldehyde(88 mg, 0.31 mmol) and methyl 3-(4-acetyl-2-methylphenyl) acrylate(67 mg, 0.31 mmol) in a procedure similar to that of Example 7 (1) as a yellow crystal (77 mg, yield 51 %). 1H NMR (CDCI3, 400ΜΗζ):δ= 0.96(3H,t,J=7Hz), 1.4-1,5(2H,m), 1.6-1,7(2H,m), 2.55(3H,s), 3.06(2H,t,J=7Hz), 3.85(3H,s), 6.47(1 H,d,J=16Hz), 7.42(1 H,d,J=15Hz), 7.61 (1 H,d,J=8Hz), 7.69(1 H,d,J=8Hz), 7.84(1 H,d,J=8Hz), 7.8-7.9(2H,m), 7.99(1 H,d,J=16Hz), 8.08(1 H,s), 8.18(1 H, d, J=15Hz). (6) Methyl 3-[4-[3-[3-butyl-6-(trifluoromethyl)benzothiophen-2-yl]propionyl]-2-methylphenyljpropionate [0153] The titled compound was prepared from the above-mentioned methyl 3-[4-[3-[3-butyl-6-(trifluoromethyl)-benzothiophen-2-yl]propenoyl]-2-methylphenyl]acrylate (77 mg, 0.16 mmol) in a procedure similar to that of Example 7 (2) as a white crystal (43 mg, yield 55 %). 1H NMR (CDCI3, 400ΜΗζ):δ= 0.95(3H,t,J=7Hz), 1.3-1,5(2H,m), 1.5-1,7(2H,m), 2.37(3H,s), 2.61 (2H,t,J=7Hz), 2.85(2H,t,J=8Hz), 2.99(2H,t,J=8Hz), 3.36(4H,s), 3.68(3H,s), 7.23(1 H,d,J=8Hz), 7.55(1 H,d,J=8Hz), 7.71 (1 H,d,J=8Hz), 7.7-7.8(2H,m), 8.02(1 H,s). (7) 3-[4-[3-[3-butyl-6-(trifluoromethyl)benzothiophen-2-yl]-propionyl]-2- methylphenyl]propionic acid [0154] The titled compound was prepared from the above-mentioned methyl 3-[4-[3-[3-butyl-6-(trifluoromethyl)-benzothiophen-2-yl]propionyl]-2-methylphenyl]propionate(43 mg, 0.088 mmol) in a procedure similar to that of Example 1 (3) as a white crystal (32 mg, yield 77 %). FAB-MS(m/e):477(M+1) 1H NMR (CDCI3, 400ΜΗζ):δ= 0.95(3H,t,J=7Hz), 1.3-1,5(2H,m), 1.5-1,7(2H,m), 2.38(3H,s), 2.66(2H,t,J=7Hz), 2.85(2H,t,J=8Hz), 3.00(2H,t,J=8Hz), 3.36(4H,s), 7.25(1 H,d,J=7Hz), 7.55(1 H,dd,J=1 Hz,8Hz), 7.6-7.8(3H,m), 8.02(1 H,s). IR(KBr,cm-1): 2956, 2927, 2861, 2360, 2341, 1712, 1681, 1608, 1569, 1428, 1411, 1365, 1328, 1278, 1257, 1214, 1157, 1114, 1083.
Example 11 3-[2-Methyl-4-[3-[3-isobutyl-6-(trifluoromethyl)benzo-thiophen-2- yl]propionyl]phenyl]propionic acid (1) 1 -[2-Fluoro-4-(trifluoromethyl)phenyl]-3-methylbutanol [0155] To mixed solution of 2M isobutylmagnesium bromide in THF (6.25 ml.) and ether (50 ml_), was added dropwise a solution of 2-fluoro-4-(trifluoromethyl)benzaldehyde (2.0g, 10 mmol) in ether (18 mL) under N2 atmosphere. The mixture was stirred at room temperature for 45 minutes, to which was added saturated aqueous ammonium chloride solution and 1M hydrochloric acid under ice-cooling. The aqueous layer was extracted with ether. The organic layer was washed with saturated aqueous sodium bicarbonate solution, saturated brine successively. After drying over anhydrous sodium sulfate, the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate = 10/1), to give the titled compound as a yellow oil (601 mg, yield 23 %). 1H NMR (CDCI3,400MHz):5= 0.97(3H,d,J=7Hz), 0.99(3H,d,J=7Hz), 1.4-1.6(1 H,m), 1.6-1,9(2H,m), 1.89(1 H,d,J=4Hz), 5.1-5.2(1 H,m), 7.28(1 H,d,J=10Hz), 7.43(1 H,d,J=8Hz), 7.63(1 H,d,J=8Hz). (2) 1 -[2-Fluoro-4-(trifluoromethyl)phenyl]-3-methylbutan-1 -one [0156] The titled compound was prepared from the above-mentioned 1-[2-fluoro-4-(trifluoromethyl)phenyl]-3-methylbutanol (600 mg, 2.40 mmol) in a procedure similar to that of Example 9 (1) as a colorless oil (596 mg, yield >99 %). 1H NMR(CDCI3,400MHz):5= 0.99(6H,d,J=7Hz), 2.2-2.4(1 H,m), 2.87(2H,dd,J=3Hz,7Hz), 7.41(1H,d,J=10Hz), 7.49(1 H,d,J=8Hz), 7.92(1 H,t,J=8Hz). (3) Methyl 3-isobutyl-6-(trifluoromethyl)benzothiophene-2-carboxylate [0157] The titled compound was prepared from the above-mentioned 1-[2-fluoro-4-(trifluoromethyl)phenyl]-3-methylbutan-1-one(596 mg, 2.40 mmol) in a procedure similar to that of Referenceexample 1 (1) as a colorless oil (501 mg, yield 66 %). 1H NMR(CDCI3,400MHz):5= 0.97(6H,d,J=7Hz), 2.0-2.2(1 H,m), 3.22(2H,d,J=7Hz), 3.94(3H,s), 7.62(1 H,d,J=8Hz), 7.95(1 H,d,=8Hz), 8.12(1 H,s). (4) [3-lsobutyl-6-(trifluoromethyl)benzothiophen-2-yl]-methanol [0158] The titled compound was prepared from the above-mentioned methyl 3-isobutyl-6-(trifluoromethyl)benzothiophen-2-carboxylate (500 mg, 1.58 mmol) in a procedure similar to that of Reference example 1 (2) (380 mg, yield 83 %). 1H NMR(CDCI3,400MHz):5= 0.95(6H,d,J=7Hz), 1.90(1 H,t,J=6Hz), 1.9-2.1 (1 H,m), 2.72(2H,d,J=7Hz), 4.96(2H,d,J=6Hz), 7.57(1 H,d,J=8Hz), 7.76(1 H,d,J=8Hz), 8.10(1 H,s). (5) 3-lsobutyl-6-(trifluoromethyl)benzothiophen-2-carboxaldehyde [0159] The titled compound was prepared from the above-mentioned [3-isobutyl-6-(trifluoromethyl)benzothiophen-2-yl]methanol(280 mg, 0.971 mmol) in a procedure similar to that of Example 9 (4) as a pale yellow crystal (250 mg, yield 90 %). 1H NMR(CDCI3,400MHz):5= 1.02(6H,d,J=7Hz), 2.0-2.2(1 H,m), 3.14(2H,d,J=7Hz), 7.65(1 H,d,J=8Hz), 7.99(1 H,d,J=8Hz), 8.17(1 H,s), 10.31 (1 Η,s). (6) Methyl 3-[4-[3-[3-isobutyl-6-(trifluoromethyl)benzo-thiophen-2-yl]propenoyl]-2-methylphenyl]acrylate [0160] The titled compound was prepared from the above-mentioned 3-isobutyl-6-(trifluoromethyl)benzothiophen-2-carboxaldehyde (250 mg, 0.873 mmol) and methyl 3-(4-acetyl-2-methylphenyl) acrylate (191 mg, 0.875 mmol) in a procedure similar to that of Example 7 (1) as a yellow crystal (250 mg, yield 71 %). 1H NMR(CDCI3,400MHz):5= 0.98(6H,d,J=7Hz), 1.9-2.1 (1 H,m), 2.55(3H,s), 2.93(2H,d,J=7Hz), 3.84(3H,s), 6.47(1 H,d,J=16Hz), 7.41(1H,d,J=15Hz), 7.60(1 H,d,J=8Hz), 7.68(1 H,d,J=8Hz), 7.83(1 H,d,J=8Hz), 7.8-7.9(2H,m), 7.99(1 H,d,J=16Hz), 8.08(1 H,s), 8.16(1 H,d,J=15Hz). (7) Methyl 3-[4-[3-[3-isobutyl-6-(trifluoromethyl)benzo-thiophen-2-yl]propionyl]-2-methylphenylpropionate [0161] The titled compound was prepared from the above-mentioned methyl 3-[4-[3-[3-isobutyl-6-(trifluoromethyl)benzothiophen-2-yl]propenoyl]-2-methylphenyl]acrylate (235 mg, 0.483 mmol) in a procedure similar to that of Example 7 (2) as a white crystal (42 mg, yield 14 %) 1H NMR(CDCI3,400MHz):5= 0.97(6H,d,J=7Hz), 1.9-2.1 (1 H,m), 2.38(3H,s), 2.61 (2H,t,J=8Hz), 2.73(2H,d,J=7Hz), 2.99(2H,d,J=8Hz), 3.36(4H,s), 3.68(3H,s), 7.23(1 H,d,J=8Hz), 7.54(1 H,d,J=8Hz), 7.6- 7.8(3H,m), 8.02(1 H,s). (8) 3-[4-[3-[3-lsobutyl-6-(trifluoromethyl)benzothiophen-2-yl]propionyl]-2-methylphenyljpropionic acid [0162] The titled compound was prepared from the above-mentioned methyl 3-[4-[3-[3-isobutyl-6-(trifluoromethyl)benzothiophen-2-yl]propionyl]-2-methylphenylpropionate (40 mg, 81 pmol) in a procedure similar to that of Example 4 (5) as a white crystal (25 mg, yield 64 %). FAB-MS(m/e):477(M+1) 1H NMR(CDCI3,400MHz):5= 0.97(6H,d,J=7Hz), 1.9-2.1 (1 H,m), 2.38(3H,s), 2.67(2H,t,J=7Hz), 2.73(2H,d,J=7Hz), 3.00(2H,t,J=7Hz), 3.36(4H,s), 7.25(1 H,d,J=7Hz), 7.54(1 H,d,J=8Hz), 7.70(1 H,d,J=8Hz), 7.75(1 H,d,J=8Hz), 7.77(1 H,s), 8.02(1 H,s).
Example 12 3-[2-methyl-4-[3-[3-isopropyl-6-(trifluoromethyl)benzo-thiophen-2- yl]propionyl]phenyl]propionic acid (1) 1 -[2-Fluoro-4-(trifluoromethyl)phenyl]-2-methylpropanol [0163] The titled compound was prepared using 0.78M isopropylmagnesium bromide in THF (30 mL) in a procedure similar to that of Example 11 (1) as a pale yellow oil (1.46 g, yield 40 %) 1H NMR(CDCI3,400MHz):5= 0.89(3H,d,J=7Hz), 0.98(3H,d,J=7Hz), 1.92(1 H,d,J=5Hz), 1.9-2.1 (1 H,m), 4.81 (1 H,t,J=5Hz), 7.28(1 H,d,J=10Hz), 7.43(1 H,d,J=8Hz), 7.60(1 H,t,J=8Hz). (2) 1 -[2-Fluoro-4-(trifluoromethyl)phenyl]-2-methyl-propan-1 -one [0164] The titled compound was prepared from the above-mentioned 1-[2-fluoro-4-(trifluoromethyl)phenyl]-2-methylpropanol (1.46 g, 6.18 mmol) in a procedure similar to that of Example 9 (1) as a pale yellow oil (1.1 g, yield 76 %). 1H NMR(CDCI3,400MHz):5= 1.20(6H,d,J=7Hz), 3.3-3.5(1 H,m), 7.41(1H,d,J=10Hz), 7.50(1 H,d,J=8Hz), 7.86(1 H,d,J=8Hz). (3) Methyl 3-isopropyl-6-(trifluoromethyl)benzothiophene-2-carboxylate [0165] The titled compound was prepared from the above-mentioned 1-[2-fluoro-4-(trifluoromethyl)phenyl]-2-methylpropan-1-one (1.1 g, 4.7 mmol) in a procedure similar to that of Reference example 1 (1) as a pale yellow oil (820 mg, yield 58 %). 1H NMR(CDCI3,400MHz):5= 1.50(6H,d,J=7Hz), 3.94(3H,s), 4.4-4.6(1 H,m), 7.59(1 H,dd,J=1 Hz,8Hz), 8.12(1 H,s), 8.21 (1 H,d,J=8Hz). (4) [3-lsopropyl-6-(trifluoromethyl)benzothiophen-2-yl]-methanol [0166] The titled compound was prepared from the above-mentioned methyl 3-isopropyl-6-(trifluoromethyl)benzothiophene-2-carboxylate (720 mg, 2.38 mmol) in a procedure similar to thatof Reference example 1 (2) as a pale yellow oil (611 mg, yield 94 %). 1H NMR(CDCI3,400MHz):5= 1.45(6H,d,J=7Hz), 1.95(1 H,t,J=5Hz), 3.4-3.5(1 H,m), 4.98(2H,d,J=5Hz), 7.55(1 H,dd,J=1 Hz,8Hz), 7.95(1 H,d,J=8Hz), 8.09(1 H,s). (5) 3-lsopropyl-6-(trifluoromethyl)benzothiophen-2-carboxaldehyde [0167] The titled compound was prepared from the above-mentioned [3-isopropyl-6-(trifluoromethyl)benzothiophene-2-yl]methanol (300 mg, 1.09 mmol) in a procedure similar to that of Example 9 (4) as a white crystal (215 mg, yield 72 %). 1H NMR(CDCI3,400MHz):5= 1.61 (6H,d,J=7Hz), 3.9-4.1 (1 H,m), 7.62(1 H,dd,J=1 Hz,8Hz), 8.15(1 H,d,J=8Hz), 8.16(1H,s), 10.47(1H,s). (6) Methyl 3-[4-[3-[3-isopropyl-6-(trifluoromethyl)-benzothiophen-2-yl]propenoyl]-2-methylphenyl]acrylate [0168] The titled compound was prepared from the above-mentioned 3-isopropyl-6-(trifluoromethyl)benzothiophen-2-carboxaldehyde (215 mg, 0.790 mmol) and methyl 3-(4-acetyl-2-methylphenyl)- acrylate (172 mg, 0.788 mmol) in a procedure similar to that of Example 7 (1) as a yellow crystal (259 mg, yield 69 %). 1H NMR(CDCI3,400MHz):5= 1.53(6H,d,J=7Hz), 2.55(3H,s), 3.7-3.8(1 H,m), 3.84(3H,s), 6.47(1 H,d,J=16Hz), 7.42(1 H,d,J=15Hz), 7.58(1 H,dd,J=1 Hz,8Hz), 7.69(1 H,d,J=8Hz), 7.8-7.9(2H,m), 8.00(1 H,d,J=16Hz), 8.05(1 H,d,J=8Hz), 8.07(1 H,s), 8.30(1 H,d,J=15Hz). (7) Methyl 3-[4-[3-[3-isopropyl-6-(trifluoromethyl)-benzothiophen-2-yl]propionyl]-2-methylphenyljpropionate [0169] The titled compound was prepared from the above-mentioned methyl 3-[4-[3-[3-isopropyl-6-(trifluoromethyl)benzothiophen-2-yl]propenoyl]-2-methylphenyl]acrylate (213 mg, 0.451 mmol) in a procedure similar to that of Example 7 (2) as a yellow crystal (151 mg, yield 70 %). 1H NMR(CDCI3,400MHz):5= 1.46(6H,d,J=7Hz), 2.37(3H,s), 2.61 (2H,t,J=8Hz), 2.99(2H,t,J=8Hz), 3.35(4H,s), 3.4-3.6(1 H,m), 3.68(3H,s), 7.23(1 H,d,J=8Hz), 7.52(1 H,d,J=8Hz), 7.73(1 H,d,J=8Hz), 7.76(1 H,s), 7.94(1 H,d,J=8Hz), 8.02(1 H,s). (8) 3-[4-[3-[3-lsopropyl-6-(trifluoromethyl)benzothiophen-2-yl]propionyl]-2-methylphenyljpropionic acid [0170] The titled compound was prepared from the above-mentioned methyl 3-[4-[3-[3-isopropyl-6-(trifluoromethyl)benzothiophen-2-yl]propionyl]-2-methylphenyl]-propionate (80 mg, 0.17 mmol) in a procedure similar to that of Example 1 (3) as a pale yellow crystal (60 mg, yield 77 %). FAB-MS(m/e):463(M+1) 1H NMR(CDCI3,400MHz):5= 1.46(6H,d,J=7Hz), 2.38(3H,s), 2.67(2H,t,J=8Hz), 3.00(2H,t,J=8Hz), 3.35(4H,s), 3.4-3.6(1 H,m), 7.25(1 H,d,J=8Hz), 7.52(1 H,dd,J=2Hz,8Hz), 7.74(1 H,dd,J=2Hz,8Hz), 7.76(1 H,s), 7.94(1 H,d,J=8Hz), 8.02(1 H,s). IR(KBr,cm-1): 3033, 2973, 2929, 2630, 1708, 1679, 1608, 1569, 1428, 1409, 1365, 1328, 1280, 1259, 1220, 1159, 1116, 1083, 1056, 1010, 941,885, 838, 815, 784, 723, 673.
Example 13 3-[4-[1 -Hydro xyimino-3-[3-isopropyl-6-(trifluoromethyl)-benzothiophen-2-yl]propyl]-2-methylphenyl]propionic acid (1) Methyl 3-[4-[1-hydroxyimino-3-[3-isopropyl-6-(trifluoromethyl)benzothiophen-2-yl]propyl]-2-methylphenyl]-propionate [0171] To a solution of methyl 3-[4-[3-[3-isopropyl-6-(trifluoromethyl)benzothiophen-2-yl]propionyl]-2-methylphenyl]propionate [Example 12 (7)] (70 mg, 0.15 mmol) in EtOH (1.5 ml.) was added a solution of hydroxylamine hydrochloride (11 mg, 0.15 mmol) and sodium acetate (14.5 mg, 0.176mmol) in water (1 mL). The mixture was heated under reflux for 1 hour, cooled at room temperature, diluted with water, and extracted with ethyl acetate. The organic layer was washed with saturated brine, and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the residue was recrystallized from ethyl acetate/hexane to give the titled compound as a pale yellow crystal (55 mg, 57 %). 1H NMR(CDCI3,400MHz):5= 1.44(6H,d,J=7Hz), 2.32(3H,s), 2.59(2H,t,J=8Hz), 2.96(2H,t,J=8Hz), 3.1-3.3(41-1,m), 3.4- 3.5(1 H,m), 3.69(3H,s), 7.16(1 H,d,J=8Hz), 7.3-7.4(2H,m), 7.52(1 H,d,J=8Hz), 7.94(1 H,d,J=8Hz), 8.04(1 H,s). (2) 3-[4-[1-Hydroxyimino-3-[3-isopropyl-6-(trifluoromethyl)benzothiophen-2-yl]propyl]-2-methylphenyl]propionic acid [0172] The titled compound was prepared from the above-mentioned methyl 3-[4-[1- hydroxyimino-3-[3-isopropyl-6-(trifluoromethyl)benzothiophen-2-yl]propyl]-2- methylphenyl]propionate (60 mg, 0.12 mmol) in a procedure similar to that of Example 1 (3) as a pale yellow crystal (41 mg, yield 70 %). FAB-MS(m/e):478(M+1) 1H NMR(CDCI3,400MHz):5= 1.43(6H,d,J=7Hz), 2.32(3H,s), 2.68(2H,t,J=7Hz), 2.98(2H,t,J=7Hz), 3.1-3.2(41-1,m), 3.4- 3.5(11-1,m), 7.20(1 H,d,J=8Hz), 7.31 (1 H,s), 1.33(1 H,d,J=8Hz), 7.52(1 H,d,J=8Hz), 7.94(1 H,d,J=8Hz), 8.03(1 H,s). IR(KBr,cm-1): 3072, 2964, 2927, 2869, 1702, 1616, 1535, 1506, 1454, 1409, 1380, 1326, 1278, 1230, 1162, 1110, 1089, 1068, 1014, 981,892, 846, 806, 755, 730, 671,611.
Example 14 3-[4-[1-[2-[3-lsopropyl-6-(trifluoromethyl)-benzothiophen-2-yl]ethyl]vinyl]-2- methylphenyl]propionic acid (1) Methyl 3-[4-[1 -[2-[3-isopropyl-6-(trifluoromethyl)-benzothiophen-2-yl]ethyl]vinyl]-2-methylphenyl]propionate [0173] To a suspension of trimethylphosphonium bromide (84 mg, 0.24 mmol) in THF (4 mL) was added sodium amide (12 mg, 0.31 mmol) under N2 atmosphere. The mixture was stirred for 30 minutes at room temperature, to which was added a solution of methyl 3-[4-[3-[3-isopropyl-6-(trifluoromethyl)benzothiophen-2-yl]propionyl]-2-methylphenyl]propionate [Example 12 (7)] (75 mg, 0.16 mmol) in THF (1 mL). The mixture was stirred for 22 hours at room temperature, treated with saturated aqueous ammonium chloride solution, and extracted with ethyl acetate. The organic layer was washed with saturated brine, and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate = 7/1), to give the titled compound as a pale yellow oil (27 mg, yield 36 %). 1H NMR(CDCI3,400MHz):0= 1.41 (6H,d,J=7Hz), 2.34(3H,s), 2.61 (2H,t,J=8Hz), 2.86(2H,t,J=8Hz), 2.96(2H,t,J=8Hz), 3.04(2H,t,J=8Hz), 3.2-3.4(1 H,m), 3.70(3H,s), 5.08(1 H,s), 5.32(1 H,s), 7.13(1 H,d,J=8Hz), 7.22(1 H,d,J=8Hz), 7.23(1 H,s), 7.51 (1 H,d,J=8Hz), 7.93(1 H,d,J=8Hz), 8.03(1 H,s). (2) 3-[4-[1-[2-[3-lsopropyl-6-(trifluoromethyl)benzothiophen-2-yl]ethyl]vinyl]-2-methylphenyljpropionic acid [0174] The titled compound was prepared from the above-mentioned methyl 3-[4-[1-[2-[3- isopropyl-6-(trifluoromethyl)benzothiophen-2-yl]ethyl]vinyl]-2-methylphenyl]-propionate (27 mg, 57 pmol) in a procedure similar to that of Example 1(3) as a yellow oil (27 mg, yield >99 %). FAB-MS(m/e):461 (M+1) 1H NMR(CDCI3,400MHz):0= 1.41 (6H,d,J=7Hz), 2.35(3H,s), 2.67(2H,t,J=7Hz), 2.86(2H,dd,J=7Hz,8Hz), 2.98(2H,t,J=7Hz), 3.03(2H,dd,J=7Hz,8Hz), 3.2-3.4(1 H,m), 5.08(1 H,s), 5.32(1 H,s),7.15(1 H,d,J=8Hz), 7.2-7.3(2H,m), 7.52(1 H,dd,J=1 Hz, 8Hz), 7.93(1 H,d,J=8Hz), 8.03(1 H,s).
Example 15 4-[3-[3-lsopropyl-6-(trifluoromethyl)benzothiophen-2-yl]-propionyl]-2- methylphenoxyacetic acid (1) 1 -(4-Hydroxy-3-methylphenyl)-3-[3-isopropyl-6-(trifluoromethyl)benzothiophen-2-yl]propan-1-one [0175] The titled compound was prepared from 3-isopropyl-6- (trifluoromethyl)benzothiophene-2-methanol (1.0 g, 3.6 mmol) in a procedure similar to that of Example 1 (1) as a yellow crystal (820 mg, yield 57 %). 1H NMR(CDCI3,400MHz):5= 1.46(6H,d,J=7Hz), 2.28(3H,s), 3.2-3.4(4H,m), 3.4-3.6(1 H,m), 5.31(1H,br s), 6.81 (1 H,d,J=8Hz), 7.52(1 H,d,J=8Hz), 7.74(1 H,dd,J=2Hz,8Hz), 7.79(1 H,s), 7.94(1 H,d,J=8Hz), 8.02(1 H,s). (2) Ethyl 4-[3-[3-isopropyl-6-(trifluoromethyl)benzothiophen-2-yl]propionyl]-2-methylphenoxyacetate [0176] The titled compound was prepared from the above-mentioned 1-(4-hydroxy-3-methylphenyl)-3-[3-isopropyl-6-(trifluoromethyl)benzothiophen-2-yl]propan-1 -one (600 mg, 1.48 mmol) in a procedure similar to that of Example 1 (2) as apale yellow oil (727 mg, yield >99 %). 1H NMR(CDCI3,400MHz):5= 1.28(3H,t,J=7Hz), 1,45(6H,d,J=7Hz), 2.31 (3H,s), 3.2-3.4(4H,m), 3.4-3.5(1 H,m), 4.24(2H,q,J=7Hz), 4.69(2H,s), 6.70 (1 H,d,J=8Hz), 7.51 (1 H,d,J=8Hz), 7.78(1 H,d,J=8Hz), 7.80(1 H,s), 7.93(1 H,d,J=8Hz), 8.01 (1 H,s). (3) 4-[3-[3-lsopropyl-6-(trifluoromethyl)benzothiophen-2-yl]-propionyl]-2-methylphenoxyacetic acid [0177] The titled compound was prepared from the above-mentioned ethyl 4-[3-[3-isopropyl-6-(trifluoromethyl)-benzothiophen-2-yl]propionyl]-2-methylphenoxyacetate (70 mg, 0.14 mmol) in a procedure similar to that of Example 1 (3) as a white crystal (43 mg, yield 65 %). FAB-MS(m/e):465(M+1) 1H NMR(CDCI3,400MHz):5= 1.46(6H,d,J=7Hz), 2.32(3H,s), 3.2-3.4(4H,m), 3.4-3.5(1 H,m), 4.77(2H,s), 6.75(1 H,d,J=8Hz), 7.52(1 H,d,J=8Hz), 7.7-7.9(2H,m), 7.94(1 H,d,J=8Hz), 8.02(1 H,s). IR(KBr,cm-1): 2964, 2927, 2792, 2584, 1749, 1670, 1600, 1581, 1506, 1427, 1402, 1365, 1328, 1278, 1245, 1184, 1159, 1132, 1116, 1083, 1056, 1012, 887, 813, 723, 682.
Example 16 4-[1-Hydroxyimino-3-[3-isopropyl-6-(trifluoromethyl)-benzothiophen-2-yl]propyl]-2-methyl-phenoxyacetic acid (1) Ethyl 4-[1-hydroxyimino-3-[3-isopropyl-6-(trifluoromethyl)benzothiophen-2-yl]propyl]-2-methylphenoxyacetate [0178] The titled compound was prepared from ethyl 4-[3-[3-isopropyl-6-(trifluoromethyl)benzothiophen-2-yl]propionyl]-2-methylphenoxyacetate [Example 15 (2)] (400 mg, 0.812 mmol) in a procedure similar to that of Example 13 (1) as a pale yellow oil (316 mg, yield 77 %). 1H NMR (CDCI3, 400MHz) : δ= 1.30(3H,t,J=7Hz), 1.44(6H,d,J=7Hz), 2.29(3H,s), 3.0-3.2(4H,m), 3.4-3.5(1 H,m), 4.27(2H,q,J=7Hz), 4.66(2H,s), 6.70(1 H,d,J=8Hz), 7.38(1 H,dd,J=2Hz,8Hz), 7.42(1 H,s), 7.52(1 H,dd,J=2Hz, 8Hz), 7.94(1 H,d,J=8Hz), 8.04(1 H,s). (2) 4-[1-Hydroxyimino-3-[3-isopropyl-6-(trifluoromethyl)-benzothiophen-2-yl]propyl]-2-methylphenoxyacetic acid [0179] The titled compound was prepared from the above-mentioned ethyl 4-[1-hydroxyimino-3-[3-isopropyl-6-(trifluoromethyl)- benzothiophen-2-yl]propyl]-2-methylphenoxyacetate (60 mg, 0.12 mmol) in a procedure similar to that of Example 1 (3) as a grayish white crystal (36 mg, yield 64 %). FAB-MS(m/e):480(M+1) 1H NMR(CDCI3,400MHz):5= 1.42(6H,d,J=7Hz), 2.27(3H,s), 3.1-3.2(4H,m), 3.3-3.5(1 H,m), 4.76(2H,s), 6.76(1 H,d,J=8Hz), 7.2-7.4(2H,m), 7.52(1 H,d,J=8Hz), 7.94(1 H,d,J=8Hz), 8.03(1 H,s). IR(KBr,cm-1): 3471, 2969, 2931, 2875, 1751, 1720, 1606, 1581, 1508, 1452, 1432, 1405, 1324, 1278, 1253, 1228, 1199, 1164, 1145, 1118, 1081, 1056, 970, 883, 821,723.
Example 17 4-[3-[3-lsopropyl-6-(trifluoromethyl)benzothiophen-2-yl]-1-methoxyiminopropyl]-2-methylphenoxyacetic acid (1) Ethyl 4-[3-[3-isopropyl-6-(trifluoromethyl)benzothiophen-2-yl]-1 - methoxyiminopropyl]-2-methylphenoxyacetate [0180] The titled compound was prepared from ethyl 4-[3-[3-isopropyl-6-(trifluoromethyl)benzothiophen-2-yl]propionyl]-2-methylphenoxyacetate [Example 15 (2)] (70 mg, 0.14 mmol) and methoxyamine hydrochloride (13 mg, 0.16 mmol) in a procedure similar to that of Example 13 (1) as a yellow oil (74 mg, yield >99 %). 1H NMR(CDCI3,400MHz):5= 1.29(3H,t,J=7Hz), 1,44(6H,d,J=7Hz), 2.29(3H,s), 3.0-3.2(4H,m), 3.3-3.5(1 H,m), 3.99(3H,s), 4.26(2H,q,J=7Hz), 4.65(2H,s), 6.68(1 H,d,J=8Hz), 7.38(1 H,dd,J=1 Hz,8Hz), 7.46(1 H,s), 7.52(1 H,dd,J=1 Hz,8Hz), 7.94(1 H,d,J=8Hz), 8.04(1 H,s). (2) 4-[3-[3-lsopropyl-6-(trifluoromethyl)benzothiophen-2-yl]-1 -methoxyiminopropyl]-2-methylphenoxyacetic acid [0181] The titled compound was prepared from ethyl 4-[3-[3-isopropyl-6-(trifluoromethyl)benzothiophen-2-yl]-1-methoxyiminopropyl]-2-methylphenoxyacetate (74 mg, 0.14 mmol) in a procedure similar to that of Example 1 (3) as a pale yellow crystal (20 mg, yield 29 %). FAB-MS(m/e):494(M+1) 1H NMR(CDCI3,400MHz):5= 1.44(6H,d,J=7Hz), 2.28(3H,s), 3.0-3.2(4H,m), 3.3-3.5(1 H,m), 3.99(3H,s), 4.71(2H,s), 6.73(1 H,d,J=8Hz), 7.41 (1 H,dd,J=2Hz,8Hz), 7.47(1 H,s), 7.52(1 H,d,J=8Hz), 7.94(1 H,d,J=8Hz), 8.03(1 H,s).
Example 18 4-[1-Benzyloxyimino-3-[3-isopropyl-6-(trifluoromethyl)-benzothiophen-2-yl]propyl]-2-methylphenoxyacetic acid (1) Ethyl 4-[1 -benzyloxyimino-3-[3-isopropyl-6-(trifluoromethyl)benzothiophen-2-yl]propyl]-2-methylphenoxyacetate [0182] To an ice-cold solution of ethyl 4-[1-hydroxyimino-3-[3-isopropyl-6-(trifluoromethyl)benzothiophen-2-yl]propyl]-2-methylphenoxyacetate [Example 16 (1)] (90 mg, 0.18 mmol) in THF(1.8 mL) was added 55% sodium hydride (12 mg, 0.27 mmol). The mixture was stirred for 10 minutes, to which was added benzyl bromide (0.03 mL, 0.3 mmol). The mixture was stirred for 72 hours at room temperature, treated with saturated aqueous ammonium chloride solution, and extracted with ethyl acetate. The organic layer was washed with saturated brine, and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate = 7/1), to give the titled compound as a colorless oil (25 mg, yield 24 %). 1H NMR(CDCI3,400MHz):5= 1.30(3H,t,J=7Hz), 1.31 (6H,d,J=7Hz), 2.29(3H,s), 3.0-3.2(4H,m), 3.2-3.4(1 H,m), 4.27(2H,q,J=7Hz), 4.65(2H,s), 5.22(2H,s), 6.69(1 H,d,J=8Hz), 7.3-7.4(5H,m), 7.40(1 H,dd,J=2Hz,8Hz), 7.47(1 H,d,J=2Hz), 7.50(1 H,d,J=8Hz), 7.90(1 H,d,J=8Hz), 8.01 (1H,s). (2) 4-[1 -Benzyloxyimino-3-[3-isopropyl-6-(trifluoromethyl)benzothiophen-2-yl]propyl]-2-methylphenoxyacetic acid [0183] The titled compound was prepared from the above-mentioned ethyl 4-[1-benzyloxyimino-3-[3-isopropyl-6-(trifluoromethyl)benzothiophen-2-yl]propyl]-2-methylphenoxyacetate (25 mg, 42 pmol) in a procedure similar to that of Example 1 (3) as a pale white crystal (13 mg, yield 55 %). FAB-MS(m/e):570(M+1) 1H NMR(CDCI3,400MHz):5= 1.30(6H,d,J=7Hz), 2.29(3H,s), 3.0-3.2(4H,m), 3.2-3.4(1 H,m), 4.71 (2H,s), 5.22(2H,s), 6.73(1 H,d,J=8Hz), 7.3-7.4(5H,m), 7.42(1 H,dd,J=2Hz,8Hz), 7.4-7.6(2H,m), 7.90(1 H,d,J=8Hz), 8.01 (1H,s).
Example 19 (as reference) [3-[2-[3-lsopropyl-6-(trifluoromethyl)benzothiophen-2-yl]-ethyl]-5-methyl-benzisoxazol-6-yloxy]acetic acid (1) 2-Chloromethyl-3-isopropyl-6-(trifluoromethyl)-benzothiophene [0184] To a solution of 3-isopropyl-6-(trifluoromethyl)-benzothiophene-2-methanol (obtained in Example 12(4), 878 mg, 3.20 mmol) in benezene (27 mL) was added dropwise a solution of thionyl chloride(0.28 mL, 3.8 mmol) in benzene (5 mL) under cooling with ice. The mixture was stirred for 3 hours at room temperature. After the solvent was removed under reduced pressure, the residue was purified by chromatography on silica gel (hexane/ethyl acetate, 10:1) to give the titled compound as a pale yellow oil (655 mg, y.70%). 1H-NMR(CDCI3, 400MHz) δ: 1.50(6H, d, J=7Hz), 3.4-3.6(1 H, m), 4.87(2H, s), 7.56(1 H, d, J=8Hz), 8.01 (1H, d, J=8Hz), 8.78(1 H, s) (2) N-[3-[2-[3-lsopropyl-6-(trifluoromethyl)benzothiophen-2-yl]ethyl]-5-methylbenzisoxazol-6-yl]acetamide [0185] To a suspension of N-(3,5-dimethylbenzisoxazol-6-yl)acetamide (381 mg, 1.87 mmol) in anhydrous THF (15 mL) was added dropwise 2M LDA (2.3 mL, 4.6 mmol) for 30 min at -78°C under N3 atmosphere. The mixture was stirred for 30 min at -78°C, to which a solution of 2-chloromethyl-3-isopropyl-6- (trifluoromethyl)benzothiophene (655 mg, 2.24 mmol)in THF(5.0 mL)was added dropwise for 30min. The mixture was stirred for 2 h at the same temperature, and then warmed to room temperature. A saturated aqueous ammonium chloride and ethyl acetate were added to the reaction mixture. The organic layer was washed with water, brine, and dried over anhydrous sodium sulfate. After the solvent was removed under reduced pressure, the residue was purified by silica gel column chromatography (hexane/ethyl acetate, 1:1) to give the titled compound as a pale yellow crystal (426 mg, yield.50%). 1H-NMR (CDCI3, 400MHz) δ: 1.34(6H, d, J=7Hz), 2.24(3H, s), 2.26(3H, br s), 3.31 (2H, t, J=8Hz), 3.3-3.4(1 H, m), 3.46(2H, t, J=8Hz), 7.09(1 H, br s), 7.19(1 H, s), 7.54(1 H, d, J=8Hz), 7.93(1 H, d, J=8Hz), 8.05(1 H, s), 8.40(1 H, br s) . (3) 6-Amino-3-[2-[3-isopropyl-6-(trifluoromethyl)benzo-thiophen-2-yl]ethyl]-5-methylbenzisoxazole [0186] The above-mentioned N-[3-[2-[3-lsopropyl-6-(trifluoromethyl)benzothiophen-2-yl]ethyl]-5-methylbenzisoxazol-6-yl]acetamide(326 mg, 0.708 mmol) was dissolved in 1M HCI (3.0 mL) and AcOH (7.0 mL). The solution was heated under reflux for 23 hours. Then reaction mixture was cooled to room temperature, diluted with 4M NaOH, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate. After the solvent was removed under reduced pressure, the residue was purified by silica gel column chromatography (hexane/ethyl acetate, 2:1) to give the title compound as a brown crystal (201 mg, yield: 68%). 1H-NMR(CDCI3, 400MHz) δ: 1.36(6H, d, J=7Hz), 2.15(3H, s), 3.26(2H, t, J=8Hz), 3.3-3.5(1 H, m), 3.4-3.5(2H, m), 3.99(2H, br s), 6.74(1 H, s), 7.09(1 H, s), 7.52(1 H, d, J=8Hz), 7.93(1 H, d, J=8Hz), 8.05(1 H, s). (4) 3-[2-[3-lsopropyl-6-(trifluoromethyl)benzothiophen-2-yl]-ethyl]-6-hydroxy-5-methylbenzisoxazole [0187] The above-mentioned 6-amino-3-[2-[3-isopropyl-6-(trifluoromethyl)benzothiophen-2-yl]ethyl]-5-methyl-benzisoxazole (100 mg, 0.239 mmol) was suspended in 25% H2SO4 (2.0 mL). A solution of sodium nitrite (25 mg, 0.36 mmol) in water (1.0 mL) was added to the suspension under cooling with ice. After the mixture was stirred for 30 min under the same conditions, and added dropwise to 75% H2SO4 (1.5 mL) that heated to 120°C. The mixture was heated for 1 h at 120°C, cooled to room temperature, diluted with ice-cold water, and extracted with ethyl acetate. The organic layer was washed with brine and dried over anhydrous sodium sulfate. After the solvent was removed, the residue was purified by silica gel column chromatography (hexane/ethyl acetate, 5:1) to give the titled compound (20 mg) as yellow crystal (20mg, yield 20%) . 1H-NMR(CDCI3, 400MHz) δ: 1.36(6H, d, J=7Hz), 2.23(3H, s), 3.2-3.5(5H, m), 6.94(1 H, s), 7.37(1 H, s), 7.53(1 H, d, J=8Hz), 7.93(1 H, d, J=8Hz), 8.04(1 H, s). (5) Ethyl 3-[2-[3-isopropyl-6-(trifluoromethyl)benzo-thiophen-2-yl]ethyl]-5- methylbenzisoxazol-6-yloxyacetate [0188] The titled compound was prepared from the above-mentioned 3-[2-[3-isopropyl-6-(trifluoromethyl)benzo-thiophen-2-yl]ethyl]-6-hydroxy-5-methylbenzisoxazole(20 mg, 0.048 mmol) in a procedure similar to that of Example 1 (2) as a yellow oil (14 mg, yield 60%). 1H-NMR(CDCI3, 400MHz) δ: 1.26(3H, t, J=7Hz), 1.35(6H, d, J=7Hz), 2.27(3H, s), 3.2-3.5(5H, m), 4.27(2H, q, J=7Hz), 4.71(2H, s), 6.72(1H, s), 7.18(1 H, s), 7.52(1H, d, J=8Hz), 7.93(1 H, d, J=8Hz), 8.18(1 H, s). (6) 3-[2-[3-lsopropyl-6-(trifluoromethyl)benzothiophen-2-yl]-ethyl]-5-methylbenzisoxazol-6-yloxyacetic acid [0189] The titled compound was prepared from the above-mentioned ethyl 3-[2-[3-isopropyl-6-(trifluoromethyl)-benzothiophen-2-yl]ethyl]-5-methylbenzisoxazol-6-yloxyacetate(14 mg, 28 pmol) in a procedure similar to that of Example 1 (3) as a pale yellow crystal(3 mg, yield 23%) FAB-MS(m/e): 478 (M+1) 1H-NMR(CDCI3, 400MHz) δ: 1.36(6H, d, J=7Hz), 2.27(3H, s), 3.30(2H, dd, J=7Hz, J=8Hz), 3.3-3.5(1 H, m), 3.46(2H, dd, J=7Hz, J=8Hz), 4.78(2H, s), 6.87(1 H, s), 7.23(1 H, d, J=8Hz), 7.52(1 H, d, J=8Hz), 7.93(1 H, d, J=8Hz), 8.05(1 H, s) .
Example 20 (as reference) N-[3-[2-[3-lsopropyl-6-(trifluoromethyl)benzothiophen-2-yl]ethyl]-5-methylbenzisoxazol- 6-yl]-N-methylglycine (1) 3-[2-[3-lsopropyl-6-(trifluoromethyl)benzothiophen-2-yl]-ethyl]-5-methyl-6-methylaminobenzisoxazole [0190] N-[3-[2-[3-lsopropyl-6-(trifluoromethyl)benzothiophen-2-yl]-ethyl]-5- methylbenzisoxazol-6-yl]acetamide (100 mg, 0.217 mmol) obtained above was dissolved in anhydrous DMF (1.0 mL). To the resulting solution was added 60% sodium hydride (10 mg, 0.26 mmol) under ice-cooling. The mixture was then stirred for 10 minutes under the same temperature and methyl iodide (0.027 mL, 0.43 mmol) was added. The mixture was stirred for 3 hours under the same temperature, diluted with water, and extracted with ethyl acetate. The organic layer was collected, washed with brine, and dried over anhydrous anhydrous sodium sulfate. The solvent was removed under reduced pressure, to give N-[3-[2-[3-isopropyl-6-(trifluoromethyl)benzo-thiophen-2-yl]ethyl]-5-methylbenzisoxazol-6-yl]-N-methylacetamide as a brown oil. The titled compound was prepared from the above-mentioned N-[3-[2-[3-isopropyl-6-(trifluoromethyl)benzothiophen-2-yl]ethyl]-5-methyl-benzisoxazol-6-yl]-N-methylacetamide in a procedure similar to that of Example 19-(3) as a brown oil (39 mg, yield 42%). 1H-NMR(CDCI3, 400MHz) δ: 1.37(6H, d, J=7Hz), 2.11 (3H, s), 2.95(3H, s), 3.25(2H, t, J=8Hz), 3.3-3.5(1 H, m), 3.4-3.5(2H, m), 4.03(1 H, br s), 6.59(1 H, s), 7.06(1 H, s), 7.52(1 H, d, J=8Hz), 7.93(1 H, d, J=8Hz), 8.04(1 H, s). (2) N-[3-[2-[3-lsopropyl-6-(trifluoromethyl)benzothiophen-2-yl]ethyl]-5-methylbenzisoxazol-6-yl]-N-methylglycine ethyl ester [0191] To a solution of 3-[2-[3-isopropyl-6-(trifluoromethyl)- benzothiophen-2-yl]ethyl]-5-methyl-6-methylaminobenzisoxazole (39 mg, 90 pmol) obtained above and diisopropylethylamine (80 pL, 0.45 mmol) in anhydrous DMF (0.45 mL) was added ethyl bromoacetate (50 pL, 0.45 mmol). The mixture was heated for 21 hours at 110°C and cooled to room temperature. Water was added to reaction mixture and extracted with ethyl aceate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and then the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (hexane/chloroform, 5:1) to give the title compound as a yellow oil (35 mg, yield 75%). 1H-NMR(CDCI3, 400MHz) δ: 1.30(3H, t, J=7Hz), 1.35(6H, d, J=7Hz), 2.28(3H, s), 2.94(3H, s), 3.29(21-1, dd, J=5Hz,J=8Hz), 3.3-3.5(1 H, m), 3.45(2H, dd, J=5Hz, 8Hz), 3.77(2H, s), 4.25(2H, q, J=7Hz), 7.19(1 H, s), 7.20(1 H, s), 7.52(1 H, d, J=8Hz), 7.93(1 H, d, J=8Hz), 8.05(1 H, s). (3) N-[3-[2-[3-lsopropyl-6-(trifluoromethyl)benzothiophen-2-yl]ethyl]-5- methylbenzisoxazol-6-yl]-N-methylglycine [0192] The titled compound was prepared from the above-mentioned N-[3-[2-[3-isopropyl-6-(trifluoromethyl)benzo-thiophen-2-yl]ethyl]-5-methylbenzisoxazol-6-yl]-N-methylglycine ethyl ester (35 mg, 68 pmol) in a procedure similar to that of Example 1 (3) as a pale yellow crystal (15 mg, yield 45%). FAB-MS(m/e) : 491 (M+1) 1H-NMR(CDCI3, 400MHz) δ: 1.35(6H, d, J=7Hz), 2.30(3H, s), 2.91 (3H, s), 3.31 (2H, dd, J=7Hz, 8Hz), 3.3-3.4(1 H, m), 3.46(2H, dd, J=7Hz, 8Hz), 3.80(2H, s), 7.2-7.3(2H, m), 7.52(1 H, d, J=8Hz), 7.93(1 H, d, J=8Hz), 8.05(1 H, s).
Example 21 (as reference) 3-[3-[2-[3-lsopropyl-6-(trifluoromethyl)benzothiophen-2-yl]-ethyl]-5- methylbenzisoxazol-6-yl]propionic acid (1) Methyl 2-bromo-3-[3-[2-[3-isopropyl-6-(trifluoromethyl)benzothiophen-2-yl]ethyl-5-methylbenzisoxazol-6-yl]propionate [0193] To a solution of 6-amino-[3-[2-[3-isopropyl-6-(trifluoromethyl)benzothiophen-2-yl]ethyl]-5-methyl] benzisoxazole (150 mg, 0.358 mmol) in methanol (1 ml_)-acetone (2 ml.) was added 48% HBr (0.17 mL, 1.4 mmol) under ice-cooling, and then the solution of sodium nitrite (30 mg, 0.43 mmol) in water (1.0 mL) was added to the resultant solution. The mixture was stirred for 2 hours under ice-cooling, and raised to room temperature. Methyl acrylate (0.23 mL, 2.5 mmol) and copper (I) oxide (5.0 mg) were added to the mixture. The resulting mixture was stirred at 40°C for 30 minutes. After the solvent was removed, the saturated aqueous sodium bicarbonate solution was added to the resultant mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, and dried over anhydrous sodium sulfate. After the solvent was removed, the residue was purified by silica gel column chromatography (hexane/ethyl acetate, 5:1) to give the titled compound as a pale yellow crystal (135 mg, yield 66%). 1H-NMR(CDCI3, 400MHz) δ: 1.33(6H, dd, J=1Hz, 7Hz), 2.33(3H, s), 3.3-3.4(4H, m), 3.47(2H, dd, J=5Hz, 8Hz), 3.57(1 H, dd, J=5Hz, 8Hz), 3.75(3H, s), 4.42(1 H, dd, J=7Hz, 8Hz), 7.23(1 H, s), 7.37(1 H, s), 7.52(1 H, dd, J=1Hz, 8Hz), 7.92(1 H, d, J=8Hz), 8.05(1 H, s). (2) Methyl 3-[3-[2-[3-isopropyl-6-(trifluoromethyl)benzo-thiophen-2-yl]ethyl]-5-methylbenzisoxazol-6-yl]acrylate [0194] To a solution of the above-mentioned methyl 2-bromo-3-[3-[2-[3-isopropyl-6-(trifluoromethyl)benzothiophen-2-yl]ethyl-5-methyl-benzisoxazol-6-yl]propionate (135 mg, 0.238 mmol) in MeOH(1.2 ml.) was added triethylamine (70 pL, 0.48 mmol). The mixture was heated for 19 hours under reflux and cooled to room temperature, diluted with saturated aqueous ammonium chloride solution and 1M HCI, and extracted with ethyl acetate. The organic layer was collected, washed with brine, dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure to give the titled compound as a brown oil (104 mg, yield 90%) . 1H-NMR(CDCI3, 400MHz) δ: 1.35(6H, d, J=7Hz), 2.41 (3H, s), 3.3-3.5(3H, m), 3.48(2H, dd, J=5, 8Hz), 3.83(3H, s), 6.44(1 H, d, J=16Hz), 7.27(1 H, s), 7.53(1 H, d, J=8Hz), 7.69(1 H, s), 7.93(1 H, d, J=8Hz), 7.99(1 H, d, J=16Hz), 8.05(1 H, s). (3) 3-[3-[2-[3-lsopropyl-6-(trifluoromethyl)benzothiophen-2-yl]ethyl]-5-methylbenzisoxazol-6-yl]acrylic acid [0195] The titled compound (75mg, yield 72%) was prepared from the above-mentioned methyl 3-[3-[2-[3-isopropyl-6-(trifluoromethyl)benzothiophen-2-yl]ethyl]-5-methylbenzisoxazol-6-yl]acrylate (104 mg, 0.213 mmol) in a procedure similar to that of Example 1 (3). 1H-NMR(CDCI3, 400MHz) δ: 1.35(6H, d, J=7Hz), 2.42(3H, s), 3.3-3.4(3H, m), 3.49(2H, dd, J=5, 8Hz), 6.47(1 H, d, J=16Hz), 7.28(1 H, s), 7.53(1 H, d, J=8Hz), 7.74(1 H, s), 7.93(1 H, d, J=8Hz), 8.05(1 H, s), 8.09(1 H, d, J=16Hz). (4) 3-[3-[2-[3-lsopropyl-6-(trifluoromethyl)benzothiophen-2-yl]ethyl]-5-methylbenzisoxazol-6-yl]propionic acid [0196] To a solution of the above-mentioned 3-[3-[2-[3-isopropyl-6- (trifluoromethyl)benzothiophen-2-yl]ethyl]-5-methylbenzisoxazol-6-yl]acrylic acid (75 mg, 0.15 mmol) in MeOH(0.8 mL) was added hydrazine monohydrate (0.15 mL, 3.1 mmol). The mixture was heated reflux for 4 hours, cooled to room temperature, diluted with ice-water and 1M HCI, and extracted with ethyl acetate. The organic layer was collected, washed with brine, dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure to give the titled compound as a brown oil (57 mg, yield 78%). FAB-MS(m/e):476(M+1) 1H-NMR(CDCI3, 400MHz) δ: 1.35(6H, d, J=7Hz), 2.32(3H, s), 2.71 (2H, t, J=7Hz), 3.07(2H, t, J=7Hz), 3.32(2H, dd, J=7Hz, 8Hz), 3.3-3.5(1 H, m), 3.47(2H, dd, J=7Hz, 8Hz), 7.25(1 H, d, J=8Hz), 7.36(1 H, s), 7.52(1 H, d, J=8Hz), 7.93(1 H, d, J=8Hz), 8.04(1 H, s). IR(KBr,cm'1) :2975, 2929, 1702, 1436, 1328, 1303, 1259, 1234, 1213, 1162, 1153, 1116, 1083, 883, 869, 815, 721,418.
Example 22 5- Hydroxy-2-methyl-4[3-[3-propyl-6-(trifluoromethyl)benzo-thiophen-2- yl]propionyl]phenoxyacetic acid (1) 1 -(2,4-Dibenzyloxy-5-methylphenyl)-3-[3-propyl-6-(trifluoromethyl)benzothiophen-2-yl]propenone [0197] To a solution of 1-(2,4-Dibenzyloxy-5-methylphenyl)-ethanone (128 mg, 0.368 mmol) in anhydrous THF(2 ml.) was added dropwise 0.5M MeONa(0.9 mL, 0.44 mmol) under icecooling. The solution was stirred for 10 minutes under same tempetature, and then a solution of 3-propyl-6-(trifluoromethyl)benzothiophen-2-carboxaldehyde (100 mg, 0.368 mmol) in anhydrous THF (1.7 mL) was added to the resultant solution. The mixture was stirred for 2.5 hours, and added 0.5 M MeONa/MeOH (2.2 mL, 1.1 mmol). The mixture was stirred at room temperature for 17.5 hours and heated reflux for 3 hours. And the mixture was cooled to room temperature, neutralized with 1M HCI under ice-cooling, and extracted with ethyl acetate. The organic layer was washed with brine, and dried over anhydrous sodium sulfate. After the solvent was removed, the residue was washed with hexane to give the titled compound as a yellow crystal (154 mg, yield 70%). 1H-NMR(CDCI3, 400MHz) δ: 0.98(3H, t, J=7Hz), 1.67(2H, q, J=7Hz), 2.25(3H, s), 2.98(2H, t, J=7Hz), 5.13(4H, s), 6.56(1 H, s),7.3-7.4(4H, m), 7.4-7.5(6H, m), 7.55(1 H, d, J=9Hz), 7.61 (1H, d, J=15Hz), 7.72(1H, s), 7.78(1 H, d, J=9Hz), 7.96(1 H, s), 8.01 (1H, d, J=15Hz). (2) 1-(2,4-Dihydroxy-5-methylphenyl)-3-[3-propyl-6-(trifluoromethyl)benzothiophen-2-yl]propenone [0198] To a solution of the above-mentioned 1-(2,4-dibenzyloxy-5-methylphenyl)-3-[3-propyl- 6- (trifluoromethyl)benzothiophen-2-yl]propenone (100 mg, 0.166 mmol) in AcOH(4.0 mL) was added cone HCI (2.0 mL). The mixture was heated for 23 hours under reflux, and then allowed to cool to room temperature and added ice-water. The mixture was neutralized with saturated aqueous sodium bicarbonate solution, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate. After the solvent was removed, the residue was purified by silica gel column chromatography (hexane/ethyl acetate, 5:1) to give the titled compound as a pale yellow crystal (66 mg, yield 94%). 1H-NMR(CDCI3, 400MHz) δ: 1.01(3H, t, J=7Hz), 1.7-1.8(2H, m),2.27(3H, s), 3.05(2H, t, J=7Hz), 6.41 (1H, s), 7.36(1 H, s), 7.45(1 H, d, J=15Hz), 7.60(1 H, d, J=9Hz), 7.84(1H, d, J=9Hz), 8.08(1 H, s), 8.21 (1H, d, J=15Hz), 8.20(1 H, s). (3) 1-(2,4-Dihydroxy-5-methylphenyl)-3-[3-propyl-6-(trifluoromethyl)benzothiophen-2-yl]propan-1-one [0199] 1-(2,4-Dihydroxy-5-methylphenyl)-3-[3-propyl-6-(trifluoromethyl)benzothiophen-2-yl]propenone was dissolved in MeOH(1.6 ml_).5% Pd-C (13 mg) was added to the solution, and the mixture was stirred for 3 hours under H3 atmosphere. The resulting mixture was filtered through celite, the filtrate was concentrated to dryness. The residue was purified by silica gel column chromatography (chloroform/methanol, 100:1) to give the brown crystal. The crystal was recrystallized from hexane-ethyl acetate, to give the titled compound as a pale yellow crystal (33 mg, yield 51%). 1H-NMR(CDCI3, 400MHz) δ: 1.01(3H, t, J=7Hz), 1.6-1.7(2H, m), 2.16(3H, s), 2.82(2H, t, J=7Hz), 3.34(4H, s), 6.35(1 H, s), 7.46(1 H, s), 7.56(1 H, d, J=9Hz), 7.71 (1H, d, J=9Hz), 8.04(1H, s), 12.45(1 H, s). (4) Ethyl 5-hydroxy-2-methyl-4-[3-[3-propyl-6- (trifluoromethyl)benzothiophen-2-yl]propionyl]phenoxyaetate [0200] In acetone (0.8 ml.) was suspended 1-(2,4-dihydroxy-5-methylphenyl)-3-[3-propyl-6-(trifluoromethyl)benzothiophen-2-yl]propan-1-one and cesium carbonate (33 mg, 0.788 mmol). After addition of 1M ethyl bromoacetate in acetone (79 pL), the mixture was stirred for 7 hours at room temperature, diluted with ice-water, and extracted with ethyl acetate. The organic layer was washed with brine, and dried over anhydrous sodium sulfate. After the solvent was removed under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate, 6:1) to give the titled compound as a pale yellow crystal (34 mg, yield 86%). 1H-NMR (CDCI3, 400MHz) δ: 1.01(3H, t, J=7Hz), 1.31(3H, t, J=7Hz), 1.6-1.7(2H, m), 2.19(3H, s), 2.83(2H, t, J=7Hz), 3.34(4H, s),4.27(2H, q, J=7Hz), 4.66(2H, s), 6.25(1 H, s), 7.47(1 H, s), 7.56(1 H, d, J=8Hz), 7.71 (1H, d, J=8Hz), 8.04(1H, s), 12.54(1H, s). (5) 5-Hydroxy-2-methyl-4-[3-[3-propyl-6-(trifluoromethyl)benzothiophen-2-yl]propionyl]phenoxyaetic acid [0201] To a mixture of ethanol (0.2 ml.) and water (0.1 mL) was suspended ethyl 5-hydroxy-2-methyl-4-[1-hydroxyimino-3-[3-propyl-6-(trifluoromethyl)-benzothiophen-2-yl]propyl] phenoxyaetate (15 mg, 0.0295 mmol) obtained above. After the addition of lithium hydroxide monohydrate (3.7 mg, 0.0885 mmol), the suspension was heated for 1 hour under reflux, and then allowed to cool to room temperature and diluted with ice-water. The mixture was acidified by addition of 1M HCI and extracted with ethyl acetate. The organic layer was washed with brine, and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the residue was recrystallized from ethyl aceate-hexane, to give the titled compound as a pale yellow crystal (9.7 mg, yield 69%). FAB-MS(m/e):481 (M+1) 1H-NMR(CDCI3, 400MHz) δ: 1.00(3H, t, J=7Hz), 1.6-1.7(2H, m), 2.19(3H, s), 2.83(2H, t, J=7Hz), 3.35(4H, s), 4.73(2H, s), 6.29(1 H, s), 7.48(1 H, s), 7.56(1 H, d, J=8Hz), 7.72(1 H, d, J=8Hz), 8.03(1 H, s), 12.53(1 H, s). IR(KBr,cm"1):2964, 2929, 2870, 2584, 2359, 1751, 1637, 1574, 1498, 1460, 1427, 1375, 1327, 1279, 1238, 1215, 1159, 1115, 1082, 1049, 980, 910, 883, 814, 762, 719, 685, 652.
Example 23 5-Hydroxy-4-[1-hydroxyimino-3-[3-propyl-6-(trifluoromethyl)benzothiophen-2-yl]propyl]-2-methyl-phenoxyaetic acid (1) Ethyl 5-hydroxy-4-[1-hydroxyimino-3-[3-propyl-6-(trifluoromethyl)-benzothiophen-2-yl]propyl]-2-methylphenoxyaetate [0202] To a solution of Ethyl 5-hydroxy-2-methyl-4-[3-[3-propyl-6- (trifluoromethyl)benzothiophen-2-yl]propionyl]-phenoxyacetate (obtained in Example 22-(4), 19 mg, 0.0381 mmol) in EtOH(0.4 mL) was added hydoxylamine hydrochloride (2.9 mg, 0.0419 mmol)and sodium acetate(3.8 mg, 0.0457 mmol) in water(0.3 mL). The mixture was heated for 10 hours under reflux and cooled to room temperature, diluted with water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the residue was recrystallized from chloroform-hexane, to give the titled compound as a white crystal (7.5 mg, yield 38%). 1H-NMR(CDCI3, 400MHz) δ: 0.99(3H, t, J=7Hz), 1.31(3H, t, J=7Hz), 1.6-1.7(2H, m), 2.19(3H, s), 2.80(2H, t, J=7Hz), 3.19(4H, s), 4.27(2H, q, J=7Hz), 4.64(2H, s), 6.34(1 H, s), 6.97(1 H, s), 7.15(1 H, s), 7.56(1 H, d, J=9Hz), 7.72(1 H, d, J=9Hz), 8.06(1 H, s), 11.04(1 H, br s). (2) 5-Hydroxy-4-[1-hydroxyimino-3-[3-propyl-6-(trifluoromethyl)-benzothiophen-2-yl]propyl]-2-methylphenoxyaetic acid [0203] To a mixture of EtOH (0.2 mL) and ^0(0.1 mL) was suspended ethyl 5-hydroxy-4-[1-hydroxyimino-3-[3-propyl-6-(trifluoromethyl)-benzothiophen-2-yl]propyl]-2- methylphenoxyaetate (7.5 mg, 0.0143 mmol) obtained above. After the addition of lithium hydroxide monohydrate (1.8 mg, 0.0429 mmol), the mixture was heated for 1 hour under reflux, and then allowed to cool to room temperature and added ice-water. The mixture was acidified by addition of 1M HCI, and extracted with ethyl acetate. The organic layer was washed with brine, and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure to give the title compound (8.0 mg, yield >99%) as a brown crystal. FAB-MS(m/e):496(M+1) 1H-NMR(CD3OD, 400MHz) δ: 1.00(3H, t, J=7Hz), 1.6-1.7(2H, m), 2.07(3H, s), 2.82(2H, t, J=7Hz), 3.19(4H, s),4.63(2H, s), 6.31(1H, s), 7.35(2H, d, J=8Hz), 7.10(1H, s), 7.57(1H, d, J=8Hz), 7.80(1 H, d, J=8Hz), 8.12(1 H, s). IR(KBr,cm"1):2958, 2931,2871,2353, 2322, 1732, 1628, 1581, 1504, 1404, 1350, 1325, 1267, 1194, 1171, 1153, 1117, 1080, 1057, 976, 941,879, 818, 769, 719, 667.
Example 24 (as reference) N-[5-Methyl-3-[2-[3-propyl-6-(trifluoromethyl)benzothiophen-2-yl]ethyl]benzisoxazol-6- yl]-N-methylglycine [0204] The foilwing compounds were obtained by the similar manner as described in Example 19 and 20. (1) N-[5-Methyl-3-[2-[3-propyl-6-(trifluoromethyl)benzo-thiophen-2-yl]ethyl]benzisoxazol-6-yl]acetamide [0205] Pale yellow crystal
Yield:38% 1H-NMR(CDCI3, 400MHz) δ: 0.94(3H, t, J=7Hz), 1.5-1.6(2H, m), 2.22(3H, s), 2.26(3H, s), 2.67(2H, t, J=7Hz), 3.2-3.5(4H, m), 7.09(1 H, br s), 7.16(1 H, s), 7.55(1 H, d, J=8Hz), 7.67(1 H, d, J=8Hz), 8.06(1 H, s), 8.40(1 H, br s). (2) N-Methyl-N-[5-methyl-3-[2-[3-propyl-6-(trifluoromethyl)benzothiophen-2-yl]ethyl]benzisoxazol-6-yl]-acetamide [0206] Pale yellow crystal
Yield:99% 1H-NMR(CDCI3, 400MHz) δ: 0.95(3H, t, J=7Hz), 1.5-1.6(2H, m),1.75(3H, s), 2.19(3H, s), 2.68(2H, t, J=7Hz), 3.20(3H, s), 3.3-3.4(2H, m), 3.4-3.5(2H, m), 7.35(2H, d, J=8Hz), 7.55(1 H, d, J=8Hz), 7.67(1 H, d, J=8Hz), 8.06(1 H, s). (3) 5-Methyl-6-methylamino-3-[2-[3-propyl-6-(trifluoromethyl) benzothiophen-2-yl]ethyl]benzisoxazole [0207] Purple crystal
Yield:82% 1H-NMR(CDCI3, 400MHz) δ: 0.95(3H, t, J=7Hz), 1.5-1,6(2H, m), 2.10(3H, s), 2.72(2H, t, J=7Hz), 2.95(3H, d, J=3Hz), 3.2-3.5(4H, m), 4.02(1 H, br s), 6.60(1 H, s), 7.05(1 H, s), 7.54(1 H, d, J=9Hz), 7.68(1 H, d, J=9Hz), 8.05(1 H, s). (4) N-[5-Methyl-3-[2-[3-propyl-6-(trifluoromethyl)benzo-thiophen-2-yl]ethyl]benzisoxazol-6-yl]-N-methylglycine ethyl ester [0208] Pale orange crystal
Yield: 78% 1H-NMR(CDCI3, 400MHz) δ: 0.95(3H, t, J=7Hz), 1.26(3H, t, J=7Hz), 1.5-1,6(2H, m), 2.28(3H, s), 2.70(2H, t, J=7Hz), 2.94(3H, s), 3.1-3.5(4H, m), 3.78(2H, s), 4.1-4.2(2H, m), 7.20(2H, s), 7.55(1 H, d, J=9Hz), 7.68(1 H, d, J=9Hz), 8.05(1 H, s). (5) N-[5-Methyl-3-[2-[3-propyl-6-(trifluoromethyl)benzo-thiophen-2-yl]ethyl]benzisoxazol-6-yl]-N-methylglycine [0209] Pale yellow crystal
Mp: 147-149°C
Yield: 88% FAB-MS(m/e):491 (M+1) 1H-NMR(CDCI3, 400MHz) δ: 0.95(3H, t, J=7Hz), 1.5-1,6(2H, m), 2.30(3H, s), 2.70(2H, t, J=7Hz), 2.92(3H, s), 3.3-3.5(4H, m), 3.80(2H, s), 7.24(2H, d, J=8Hz), 7.56(1 H, d, J=8Hz), 7.69(1 H, d, J=8Hz), 8.06(1 H, s). IR(KBr,cm"1):2958, 2931,2873, 1738, 1622, 1516, 1489, 1466, 1441, 1406, 1369, 1322, 1257, 1171, 1105, 1078, 1061,991,943,876, 845, 822, 793, 719, 702, 669, 656.
Example 25 (as reference) [5-Methyl-3-[2-[3-propyl-6-(trifluoromethyl)benzothiophen-2-yl]ethyl]benzisoxazol-6-yloxy]acetic acid [0210] The foilwing compounds were obtained by the similar manner as described in Example 19. (1) 6-Amino-5-methyl-3-[2-[3-propyl-6-(trifluoromethyl)-benzothiophen-2-yl]ethyl]benzisoxazole [0211] Orange crystal
Yield:87% 1H-NMR (CDCI3, 400MHz) δ: 0.95(3H, t, J=8Hz), 1.5-1,6(2H, m), 2.14(3H, s), 2.71 (2H, t, J=7Hz), 3.2-3.5(4H, m), 3.99(2H, s), 6.75(1 H, s), 7.08(1 H, s), 7.55(1 H, d, J=8Hz), 7.68(1 H, d, J=8Hz), 8.05(1 H, s). (2) 6-Hydroxy-5-methyl-3-[2-[3-propyl-6-(trifluoromethyl)benzothiophen-2-yl]ethyl]benzisoxazole [0212] Orange crystal
Yield: 16% 1H-NMR (CDCI3, 400MHz) δ: 0.95(3H, t, J=7Hz), 1.5-1,6(2H, m), 2.23(3H, s), 2.70(2H, t, J=7Hz), 3.2-3.5(4H, m), 5.35(1 H, s), 6.93(1 H, s), 7.16(1 H, s), 7.55(1 H, d, J=9Hz), 7.68(1 H, d, J=9Hz), 8.05(1 H, s). (3) Ethyl [5-methyl-3-[2-[3-propyl-6-(trifluoromethyl)-benzothiophen-2- yl]ethyl]benzisoxazol-6-yloxy]acetate [0213] Pale yellow crystal
Yield:68% 1H-NMR (CDCI3, 400MHz) δ: 0.95(3H, t, J=8Hz), 1.31(3H, t, J=7Hz), 1.5-1.6(2H, m), 2.27(3H, s), 2.72(2H, t, J=7Hz), 3.2-3.5(4H, m), 4.28(2H, q, J=7Hz), 4.71 (2H, s), 6.82(1 H, s), 7.20(1 H, s), 7.55(1 H, d, J=8Hz), 7.69(1 H, d, J=8Hz), 8.05(1 H, s). (4) [5-Methyl-3-[2-[3-propyl-6-(trifluoromethyl)benzo-thiophen-2-yl]ethyl]benzisoxazol- 6-yloxy]acetic acid [0214] Pale yellow crystal
Yield:99% FAB-MS (m/e): 478(M+1) 1H-NMR (CDCI3, 400MHz) δ: 0.95(3H, t, J=7Hz), 1.5-1,6(2H, m), 2.26(3H, s), 2.70(2H, t, J=7Hz), 3.2-3.5(4H, m), 4.78(2H, s), 6.87(1 H, s), 7.20(1 H, s), 7.55(1 H, d, J=8Hz), 7.69(1 H, d, J=8Hz), 8.05(1 H, s).
Example 26 (as reference) 3-[5-Methyl-3-[2-[3-propyl-6-(trifluoromethyl)benzothio-phen-2-yl]ethyl]benzisoxazol-6-yl]propionic acid [0215] The follwing compounds were obtained by the similar manner as described in Example 21. (1) Methyl 2-bromo-3-[5-methyl-3-[2-[3-propyl-6-(trifluoromethyl)benzothiophen-2-yl]ethyl]benzisoxazol-6-yl]propionate [0216] Yellow oil
Yield:70% 1H-NMR (CDCI3, 400MHz) δ: 0.94(3H, t, J=7Hz), 1.5-1,6(2H, m), 2.32(3H, s), 2.68(2H, t, J=7Hz), 3.3-3.6(6H, m), 3.75(3H, s), 4.42(1 H, t, J=7Hz), 7.23(1 H, s), 7.37(1 H, s), 7.55(1 H, d, J=8Hz), 7.67(1 H, d, J=8Hz), 8.05(1 H, s). (2) Methyl 3-[5-methyl-3-[2-[3-propyl-6-(trifluoromethyl)benzothiophen-2- yl]ethyl]benzisoxazol-6-yl]acrylate [0217] Pale orange crystal
Yield:94% 1H-NMR (CDCI3, 400MHz) δ: 0.95(3H, t, J=7Hz), 1.5-1,6(2H, m), 2.40(3H, s), 2.70(2H, t, J=7Hz), 3.3-3.5(4H, m), 3.84(3H, s), 6.44(1 H, d, J=16Hz), 7.25(1 H, s), 7.55(1 H, d, J=9Hz), 7.68(1 H, d, J=9Hz), 7.70(1 H, s), 8.00(1 H, d, J=16Hz), 8.06(1 H, s). (3) 3-[5-Methyl-3-[2-[3-propyl-6-(trifluoromethyl)benzo-thiophen-2-yl]ethyl]benzisoxazol-6-yl]acrylic acid [0218] Pale yellow crystal
Yield: 97% 1H-NMR (CDCI3, 400MHz) δ: 0.95(3H, t, J=7Hz), 1.5-1,6(2H, m), 2.41 (3H, s), 2.70(2H, t, J=8Hz), 3.3-3.5(4H, m), 6.47(1 H, d, J=16Hz), 7.26(1 H, s), 7.55(1 H, d, J=9Hz), 7.68(1 H, d, J=9Hz), 7.73(1 H, s), 8.06(1 H, s), 8.07(1 H, d, J=16Hz). (4)3-[5-Methyl-3-[2-[3-propyl-6-(trifluoromethyl)benzo-thiophen-2-yl]ethyl]benzisoxazol-6-yl]propionic acid [0219] Pale yellow crystal
Yield:72% FAB-MS (m/e): 476(M+1) 1H-NMR (CDCI3, 400MHz) δ: 0.94(3H, t, J=7Hz), 1.5-1,6(2H, m), 2.32(3H, s), 2.70(2H, t, J=7Hz), 2.71 (2H, t, J=7Hz), 3.07(2H, t, J=7Hz), 3.3-3.5(4H, m), 7.24(1 H, s), 7.37(1 H, s), 7.55(1 H, d, J=8Hz), 7.69(1 H, d, J=8Hz), 8.05(1 H, s). IR(KBr, cm'1):2964, 2929, 2376, 2349, 1705, 1624, 1516, 1518, 1458, 1437, 1406, 1360, 1327, 1257, 1217, 1155, 1113, 1082, 1057, 957, 883, 843, 818, 719, 673, 648.
Example 27 (as reference) 2-[3-[2-[3-lsopropyl-6-(trifluoromethyl) benzothiophen-2-yl]ethyl]benzisoxazol-6- yloxy]propionic acid [0220] The foilwing compounds were obtained by the similar manner as described in Example 19. (1) Ethyl 2-[3-[2-[3-lsopropyl-6-(trifluoromethyl)benzo-thiophen-2-yl]ethyl]benzisoxazol-6-yloxy]propionate [0221] Pale yellow oil
Yield :26% 1H-NMR (CDCI3, 400MHz) δ: 1.26(3H, t, J=7Hz), 1.36(6H, d, J=7Hz), 1.68(3H, d, J=7Hz), 2.26(3H,s), 3.1-3.2(2H, m), 3.3-3.4(1H, m), 3.4-3.5(2H, m), 4.22(2H, q, J=7Hz), 4.81(1 H, q, J=7Hz), 6.79(1 H, s), 7.20(1 H, s), 7.52(1 H, d, J=9Hz), 7.93(1 H, d, J=9Hz), 8.05(1 H, s). (2) 2-[3-[2-[3-lsopropyl-6-(trifluoromethyl)benzothio-phen-2-yl]ethyl]benzisoxazol-6-yloxy]propionic acid [0222] Pale yellow crystal
Yield 98%
Mp:159-161°C FAB-MS (m/e): 492(M+1) 1H-NMR (CDCI3, 400MHz) δ: 1.35(6H, d, J=7Hz), 1.74(3H, d, J=7Hz),2.25(3H, s),3.29(2H, dd, J=6Hz,8Hz), 3.3-3.4(1 H, m), 3.45(2H, dd, J=6Hz, 8Hz), 4.88(1 H, q, J=7Hz), 6.85(1 H, s), 7.21 (1H, s), 7.52(1 H, d, J=8Hz), 7.92(1 H, d, J=8Hz), 8.04(1 H, s). IR(KBr, cm-1): 2964, 2927, 2854, 2359, 1726, 1622, 1604, 1518, 1448, 1375, 1329, 1300, 1275, 1244, 1151, 1119, 1082, 1045, 1003, 931,881,814, 721,673.
Example 28 (as reference) N-[3-[2-[3-lsopropyl-6-(trifluoromethyl)benzothiophen-2-yl]ethyl]benzisoxazol-6-yl]-N- methylglycine [0223] The foilwing compounds were obtained by the similar manner as described in Example 19. (1) N-[3-[2-[3-lsopropyl-6-(trifluoromethyl)benzothio-phen-2-yl]ethyl]benzisoxazol-6-yl]acetamide [0224] Pale yellow crystal
Yield:37% 1H-NMR (CD3OD, 400MHz) δ: 1.28(6H, d, J=7Hz), 2.15(3H, s), 3.3-3.4(1 H, m), 3.37(2H, t, J=7Hz), 3.49(2H, t, J=7Hz), 7.24(1 H, dd, J=1Hz, 8Hz), 7.52(1 H, dd, J=1Hz, 8Hz), 7.55(1 H, dd, J=8Hz), 8.00(1 H, d, J=8Hz), 8.10(2H, s). (2) N-[3-[2-[3-lsopropyl-6-(trifluoromethyl)benzothio-phen-2-yl]ethyl]benzisoxazol-6-yl]-N-methylacetamide [0225] Yellow oil
Yield:66% 1H-NMR (CDCI3, 400MHz) δ: 1.37(6H, d, J=7Hz), 1.91(3H, br s), 3.32(3H, s), 3.3-3.4(1 H, m),3.39(2H, dd, J=6,7Hz),3.51 (2H,dd,J=6,7Hz), 7.12(1 H, d, J=8Hz), 7.42(1 H, d, J=1Hz), 7.52(1 H, dd, J=1,8Hz), 7.5 7(1 H, d, J=8Hz), 7.93(1 H, d, J=8Hz), 8.04(1 H,s). (3) 3-[2-[3-lsopropyl-6-(trifluoromethyl)benzothiophen-2-yl]ethyl]-6-methylaminobenzisoxazole [0226] Pale brown crystal
Yield :85% 1H-NMR (CDCI3, 400MHz) δ: 1.37(6H, d, J=7Hz), 2.90(3H, s), 3.26(2H, dd, J=7Hz, 8Hz), 3.3-3.4(1 H, m), 3.44(2H, dd, J=7Hz, 8Hz), 4.17(1 H,br s), 6.52(1 H, dd, J=2,9Hz), 6.57(1 H, d, J=2Hz), 7.23(1 H, d, J=9Hz), 7.51 (1H, d, J=9Hz), 7.92(1 H, d, J=9Hz), 8.04(1 H,s). (4) N-[3-[2-[3-lsopropyl-6-(trifluoromethyl)benzothio-phen-2-yl]ethyl]-N-methylglycine ethyl ester [0227] Pale yellow crystal
Yield:74% 1H-NMR (CDCI3, 400MHz) δ: 1.25(3H, t, J=7Hz), 1.38(6H, d, J=7Hz),3.15(3H, s), 3.27(2H, dd, J=7Hz, 8Hz), 3.3-3.4(1 H, m), 3.45(2H, dd, J=7Hz, 8Hz), 4.13(2H, s), 4.19(2H, q, J=7Hz), 6.66(1 H, dd, J=1Hz, 9Hz), 6.69(1 H, d, J=1Hz), 7.34(1 H, d, J=9Hz), 7.52(1 H, d, J=9Hz), 7.93(1 H, d, J=9Hz), 8.04(1 H,s). (5) N-[3-[2-[3-lsopropyl-6-(trifluoromethyl)benzothio-phen-2-yl]ethyl]-N-methylglycine [0228] Pale yellow crystal
Mp:153-156°C
Yield:96% FAB-MS (m/e): 477(M+1) 1H-NMR (CDCI3, 400MHz) δ: 1.38(6H,d,J=7Hz),3.15(3H,s),3.25(2H,dd,J=7,8Hz),3.3-3.4(1 H, m), 3.45(2H, dd, J=7,8Hz), 4.19(2H, s), 6.67(1H, dd, J=1,9 Hz), 6.71(1H, d, J=1Hz), 7.36(1H, d, J=9Hz), 7.51(1H, d, J=9Hz), 7.92(1 H, d, J=9Hz), 8.03(1 H,s).
[0229] IR(KBr, cm’1) :2972, 2871, 2395, 2350, 1747, 1626, 1520, 1477, 1404, 1371, 1327, 1259, 1246, 1211, 1178, 1161, 1113, 1080, 1059, 976, 955, 881,817, 723, 642, 615.
Example 29
Pharmacological Experimentals
I. Procedures of Experimental
Transfection [0230] The PPAR activating effects of test compounds were measured by the following method.
[0231] A receptor expression plasmid (pSG5-GAL4-hPPAR a or γ or δ LBD), a luciferase expression plasmid (pUC8-MH100x4-TK-Luc) and β-galactosidase (pCMX-P-GAL) expression plasmid (Kliewer, S.A., et. al., (1992) Nature, 358: 771-774) are transfected into CV-1 cells (ATCC), American type culture collection)). Subsequently, it is incubated for approximately 40 hours in the presence of the test compound. Then, the luciferase activity and β-GAL activity are measured on the soluble cells. The luciferase activity is calibrated by the β-GAL activity. A relative ligand activity is calculated in consideration of a luciferase activity (assigned to 100%) of cells treated with GW-590735 (PPAR α-selective agonist), Rosiglitazone (PPAR y selective agonist), or GW-501516 (PPAR δ selective agonist).
Experimental Results [0232] TABLE 24
* = reference example PPAR activity: relative value (%) of the test compound to 100% of the control compound is calculated, and the activity is shown as EC50 (pM), that is, the concentration of the test compound giving 50% of the relative value.
a: GW-590735 = 10'6 M
y: Rosiglitazone = 10'5 M
δ: GW-501516 = 10'7 M
[0233] As is clear from Table 24, the compounds of the invention show an excellent PPAR δ activating effect.
Example 30 (as reference)
Pharmacological Experimentals (procedures of Experimental) [0234] The PPAR activating effect (EC50 (pM)) was measured on the compounds of Example 19, 21 and GW-501516 by the method described in Example 29. TABLE 25
[0235] As is clear from Table 25, the compounds of Example 19 and 21 show a selectivity of
PPAR δ-activating effect superior to that of the GW-501516.
Example 31 [0236] The PPAR activating effect was measured on the compound of Examples by the method described in Example 29.
Experimental Results [0237] TABLE 26 (* = reference example)
PPAR activity: relative value (%) of the test compound (10"7M) to 100% of the control compound
a: GW-590735 - 10’6M
y: Rosiglitazone - 10'5 M
δ: GW-501516- 10’7M
[0238] As is clear from Table 26, the compound of Examples 22 and 23 according to the invention shows an excellent PPAR δ activating effect.
REFERENCES CITED IN THE DESCRIPTION
This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.
Patent documents cited in the description • WO01000603A [00041 • W02005090920A [00061 • WQ02014291A [0006] • WQQ2076957A [00081 • WQ03016291A [00061 • WQ03033493A [00061 • W02007004733A [00081 • WQ2007119887A [0006] [01351 • WQ2008Q18175A [00061
Non-patent literature cited in the description . Proc. Natl. Acad. Sci. USA, 1994, vol. 91,7335-7359 [0002] • KLIEWER, S.A.Nature, 1992, vol. 358, 771-774 [02311

Claims (5)

1. Forbindelse eller et farmakologisk acceptabelt salt deraf valgt fra gruppen bestående af: 2-methyl-4-[3-(3-methylbenzothiophen-2-yl)propionyl] phenoxyeddikesyre, 2-methyl-2-[2-methyl-4-[3-(3-methylbenzothiophen-2-yl)- propionyl]phenoxy]propionsyre, 2-methyl-4-[3-[3-methyl-5-(trifluormethyl)benzothiophen-2-yl] propionyl] phenoxyeddikesyre, 2-methyl-2-[2-methyl-4-[3-[3-methyl-5-(trifluormethyl)-benzothiophen-2- yl]propionyl]phenoxy]propionsyre, 2-methyl-4-[3-[3-methyl-6-(trifluormethyl)benzothiophen-2-yl] propionyl] phenoxyeddikesyre, 2- methyl-2-[2-methyl-4-[3-[3-methyl-6-(trifluormethyl)-benzothiophen-2-yl]propionyl]phenoxy]propionsyre, 3- [4-[3-[3-methyl-6-(trifluormethyl)benzothiophen-2-yl]-propionyl]-2-methylphenyl]propionsyre, 3-[4-[3-[3-ethyl-6-(trifluormethyl)benzothiophen-2-yl]propionyl]-2- methylphenyl]propionsyre, 3-[2-methyl-4-[3-[3-propyl-6-(trifluormethyl)benzothiophen-2-yl] propionyl] phenyl] propionsyre, 3-[2-methyl-4-[3-[3-butyl-6-(trifluormethyl)benzothiophen-2-yl] propionyl] phenyl] propionsyre, 3-[2-methyl-4-[3-[3-isobutyl-6-(trifluormethyl)benzothiophen-2-yl] propionyl] phenyl] propionsyre, 3-[2-methyl-4-[3-[3-isopropyl-6-(trifluormethyl)benzothio-phen-2-yl] propionyl] phenyl] propionsyre, 3-[4-[l-hydroxyimino-3-[3-isopropyl-6-(trifluormethyl)benzo-thiophen-2- yl]propyl]-2-methylphenyl]propionsyre, 3- [4-[ l-[2-[3-isopropyl-6-(trifluormethyl)benzothiophen-2-yl]ethyl] vinyl]-2-methylphenyl]propionsyre, 4- [3-[3-isopropyl-6-(trifluormethyl)benzothiophen-2-yl]propionyl]-2-methylphenoxyeddikesyre, 4-[l-hydroxyimino-3-[3-isopropyl-6-(trifluormethyl)benzothio-phen-2- yl]propyl]-2-methylphenoxyeddikesyre, 4-[3-[3-isopropyl-6-(trifluormethyl)benzothiophen-2-yl]-l-methoxyiminopropyl]-2-methylphenoxyeddikesyre, og 4- [l-benzyloxyimino-3-[3-isopropyl-6-(trifluormethyl)benzo-thiophen-2-yl]propyl]-2-methylphenoxyeddikesyre; 5- hydroxy-2-methyl-4-[3-[3-propyl-6-(trifluormethyl)benzo-thiophen-2-yl]propionyl]phenoxyeddikesyre; og 5-hydroxy-4-[l-hydroxyimino-3-[3-propyl-6-(trifluormethyl)- benzothiophen-2-yl]propyl]-2-methylphenoxyeddikesyre.
2. Aktivator af peroxisom-proliferator-aktiveret receptor δ, der indeholder som en effektiv komponent en forbindelse eller et farmakologisk acceptabelt salt deraf defineret i krav 1.
3. Forbindelsen eller et farmakologisk acceptabelt salt deraf defineret i krav 1 til anvendelse i en fremgangsmåde til behandling og/eller profylakse af en sygdom medieret af peroxisom-proliferator-aktiveret receptor.
4. Forbindelsen eller et farmakologisk acceptabelt salt deraf til anvendelse ifølge krav 3, hvor sygdommen er hyperlipidemi, dyslipidemi, hypercholesterolemi, hypertriglyceridemi, hypo-HDL-emi, hyper-LDL-emi og/eller non-HLD-emi, hyper-VLDL-emi, dyslipoproteinemi, apolipoprotein A-I hypoproteinemi, atherosklerose, sygdom af arteriosklerose, sygdom af kardiovaskulær systemer, cerebrovaskulær sygdom, perifer kredsløbssygdom, stofskiftesyndrom, syndrom X, fedme inkluderende fedttype af indre organer, diabetes, hyperglykæmi, insulinresistens, nedsat glukosetolerance, hyperinsulinisme, diabetisk komplikation, hjertesvigt, hjerte i nfa rkt, kardiomyopati, hypertension, fedtlever, ikke-alkoholisk fedthepatitis, thrombus, Alzheimers sygdom, neurodegenerativ sygdom, demyeliniserende sygdom, multipel sklerose, adrenal leukodystrofi, dermatitis, psoriasis, akne, hudaldring, trikose, inflammation, arthritis, astma, hypersensitiv tarmsyndrom, ulcerativ colitis, Crohns sygdom, pancreatitis eller kræft, som inkluderer kolonkræft, tyktarmskræft, hudkræft, brystkræft, prostatakarcinom, kræft i æggestokken eller lungekræft.
5. Forbindelsen eller et farmakologisk acceptabelt salt deraf til anvendelse ifølge krav 4, hvor sygdommen er dyslipidemi, stofskiftesyndrom, fedme inkluderende fedttype af indre organer, atherosklerose eller sygdom associeret dermed eller diabetes.
DK09731677.2T 2008-04-15 2009-04-15 ACTIVATOR FOR PEROXISOM PROLIFERATOR-ACTIVATED RECEPTOR DK2277874T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008105899 2008-04-15
PCT/JP2009/057946 WO2009128558A1 (en) 2008-04-15 2009-04-15 Activator for peroxisome proliferator-activated receptor

Publications (1)

Publication Number Publication Date
DK2277874T3 true DK2277874T3 (en) 2018-08-06

Family

ID=41199240

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09731677.2T DK2277874T3 (en) 2008-04-15 2009-04-15 ACTIVATOR FOR PEROXISOM PROLIFERATOR-ACTIVATED RECEPTOR

Country Status (24)

Country Link
US (1) US8648208B2 (en)
EP (2) EP2277874B1 (en)
JP (1) JP5474769B2 (en)
KR (2) KR101710340B1 (en)
CN (2) CN104672220B (en)
AU (1) AU2009236877B2 (en)
BR (1) BRPI0911197A2 (en)
CA (1) CA2721339C (en)
CY (1) CY1120477T1 (en)
DK (1) DK2277874T3 (en)
ES (1) ES2683012T3 (en)
HR (1) HRP20181168T1 (en)
HU (1) HUE039145T2 (en)
IL (1) IL208754A (en)
LT (1) LT2277874T (en)
MX (1) MX2010011252A (en)
NZ (1) NZ588612A (en)
PL (1) PL2277874T3 (en)
PT (1) PT2277874T (en)
RU (1) RU2501794C2 (en)
SI (1) SI2277874T1 (en)
TW (1) TWI440633B (en)
WO (1) WO2009128558A1 (en)
ZA (1) ZA201007392B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013006769A (en) * 2009-10-08 2013-01-10 Nippon Chemiphar Co Ltd Activator for peroxisome proliferator activating receptor
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013068486A1 (en) 2011-11-08 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of male infertility
US20170101209A1 (en) * 2015-10-08 2017-04-13 Cash J Viedt Growler
US11332457B2 (en) * 2017-11-30 2022-05-17 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Aromatic compound, pharmaceutical composition and use thereof
CN111393405B (en) * 2019-01-02 2022-11-25 中国科学院上海药物研究所 Fluorine-containing substituted benzothiophene compounds, and pharmaceutical composition and application thereof
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2022189856A1 (en) * 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956379A (en) * 1990-02-13 1990-09-11 Bristol-Myers Squibb Company Pyrazole carboxylic acids and esters and inhibition of blood platelet aggregation therewith
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
GB9027023D0 (en) 1990-12-12 1991-01-30 Wellcome Found Anti-atherosclerotic aryl compounds
HUT64023A (en) 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
CA2090283A1 (en) 1992-02-28 1993-08-29 Nobuyuki Hamanaka Phenoxyacetic acid derivatives
GB9426448D0 (en) 1994-12-30 1995-03-01 Wellcome Found Process
AU714054B2 (en) * 1995-01-06 1999-12-16 Toray Industries, Inc. Benzene-fused heterocyclic derivatives and use of the same
CA2171702A1 (en) * 1995-03-14 1996-09-15 Takashi Sohda Benzofuran compounds and their use
WO1996035688A1 (en) 1995-05-08 1996-11-14 Nippon Chemiphar Co., Ltd. 2,4-thiazolidinedione or oxazolidinedione derivatives and hypoglycemic agent
DE69712042T2 (en) 1996-01-22 2002-10-02 Fujisawa Pharmaceutical Co THIAZOLYLBENZOFURAN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE
JP2002503202A (en) 1996-02-02 2002-01-29 メルク エンド カンパニー インコーポレーテッド Antidiabetic drugs
US20020032330A1 (en) * 1996-12-24 2002-03-14 Yutaka Nomura Propionic acid derivatives
US6300364B1 (en) * 1997-07-24 2001-10-09 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions with cholesterol-lowering effect
US6589969B1 (en) * 1998-10-16 2003-07-08 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
JP4618845B2 (en) 1999-06-09 2011-01-26 杏林製薬株式会社 Substituted phenylpropionic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha agonists
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
DE60005973T2 (en) 1999-08-27 2004-05-13 Eli Lilly And Co., Indianapolis BIARYL-OXA (THIA) ZOL DERIVATIVES AND THEIR USE AS PPARS MODULATORS
PE20011010A1 (en) 1999-12-02 2001-10-18 Glaxo Group Ltd OXAZOLES AND THIAZOLES REPLACED AS AGONIST OF THE RECEPTOR ACTIVATED BY THE HUMAN PEROXISOMAS PROLIFERATOR
JP2001261674A (en) * 2000-03-22 2001-09-26 Mitsui Chemicals Inc Benzothiophene derivative and intranuclear receptor agonist
JP2001354671A (en) * 2000-04-14 2001-12-25 Nippon Chemiphar Co Ltd ACTIVATOR FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR delta
US6787552B2 (en) * 2000-08-11 2004-09-07 Nippon Chemiphar Co., Ltd. PPAR delta activators
GB0031103D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
WO2002067912A2 (en) 2001-02-22 2002-09-06 Smithkline Beecham Corporation Method for treating ppar gamma mediated diseases or conditions
JP4157381B2 (en) * 2001-03-23 2008-10-01 日本ケミファ株式会社 Activator of peroxisome proliferator-responsive receptor
GB0111523D0 (en) 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
DK1424330T3 (en) 2001-08-10 2012-01-16 Nippon Chemiphar Co Activator for peroxisome proliferator-responsive receptor delta
ES2260456T3 (en) 2001-08-29 2006-11-01 Warner-Lambert Company Llc ORAL ANTIDIABETIC AGENTS.
US20030171377A1 (en) * 2001-08-29 2003-09-11 Bigge Christopher Franklin Antidiabetic agents
EP1445258B1 (en) 2001-10-12 2009-06-24 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator-activated receptor delta
JP2003292439A (en) 2002-02-04 2003-10-15 Sumitomo Pharmaceut Co Ltd Ppar activation agent composed of new pyrrole derivative
WO2003099793A1 (en) 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited 1,2-azole derivatives with hypoglycemic and hypolipidemic activity
WO2004007439A1 (en) 2002-07-10 2004-01-22 Sumitomo Pharmaceuticals Co., Ltd. Biaryl derivatives
US6800655B2 (en) * 2002-08-20 2004-10-05 Sri International Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents
US7553867B2 (en) 2002-09-06 2009-06-30 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
US20050080115A1 (en) * 2002-10-28 2005-04-14 Lone Jeppesen Novel compounds, their preparation and use
PL376704A1 (en) * 2002-10-28 2006-01-09 Novo Nordisk A/S Novel compounds useful in treating ppar mediated diseases
AU2003296401A1 (en) 2003-01-06 2004-08-10 Eli Lilly And Company A pyrazole derivative as ppar modulator
CA2510516A1 (en) 2003-01-06 2004-07-29 Eli Lilly And Company Fused heterocyclic derivatives as ppar modulators
EP1583754A1 (en) 2003-01-06 2005-10-12 Eli Lilly And Company Thiophene derivative ppar modulators
WO2004071509A1 (en) 2003-02-12 2004-08-26 Nippon Chemiphar Co., Ltd. Oligodendrocyte differentiation promoters
TW200526588A (en) 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
WO2005054213A1 (en) 2003-12-02 2005-06-16 Shionogi & Co., Ltd. Isoxazole derivative having agonistic activity against peroxisome proliferator-activated receptor
GB0403148D0 (en) 2004-02-12 2004-03-17 Smithkline Beecham Corp Chemical compounds
ATE519096T1 (en) 2004-03-16 2011-08-15 Nxp Bv MAGNETORESISTIC SENSOR WITH TEST MODE ACTIVATION
FR2869611B1 (en) * 2004-05-03 2006-07-28 Merck Sante Soc Par Actions Si HEXENOIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND THERAPEUTIC APPLICATIONS
US20060014785A1 (en) 2004-05-25 2006-01-19 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
WO2006075638A1 (en) * 2005-01-14 2006-07-20 Dainippon Sumitomo Pharma Co., Ltd. Novel heteroaryl derivative
JPWO2006090920A1 (en) * 2005-02-28 2008-07-24 日本ケミファ株式会社 Activator of peroxisome proliferator activated receptor δ
CA2609980C (en) * 2005-05-27 2015-10-13 Queen's University At Kingston Treatment of protein folding disorders
AU2006266711A1 (en) * 2005-07-06 2007-01-11 Nippon Chemiphar Co., Ltd. Activator of peroxisome proliferator activated receptor delta
CN102643248A (en) 2006-04-18 2012-08-22 日本化学医药株式会社 Activating agent for peroxisome proliferator activated receptor
WO2008016175A1 (en) 2006-08-03 2008-02-07 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator activated receptor
UA57596U (en) * 2010-07-05 2011-03-10 Товариство З Обмеженою Відповідальністю "Станіславська Торгова Компанія" “frankivska hostyna”, special vodka

Also Published As

Publication number Publication date
PT2277874T (en) 2018-08-10
AU2009236877A1 (en) 2009-10-22
SI2277874T1 (en) 2019-01-31
CA2721339A1 (en) 2009-10-22
ES2683012T3 (en) 2018-09-24
JPWO2009128558A1 (en) 2011-08-04
RU2010146166A (en) 2012-05-20
US8648208B2 (en) 2014-02-11
TWI440633B (en) 2014-06-11
MX2010011252A (en) 2010-11-30
KR20170021918A (en) 2017-02-28
KR101710340B1 (en) 2017-02-27
CY1120477T1 (en) 2019-07-10
EP2277874A1 (en) 2011-01-26
TW200946514A (en) 2009-11-16
IL208754A (en) 2016-04-21
AU2009236877B2 (en) 2014-01-23
LT2277874T (en) 2018-10-10
PL2277874T3 (en) 2018-11-30
HRP20181168T1 (en) 2018-11-02
KR101871665B1 (en) 2018-06-27
CN104672220B (en) 2017-09-22
CA2721339C (en) 2017-01-24
CN104672220A (en) 2015-06-03
EP2277874A4 (en) 2011-10-12
CN102083810A (en) 2011-06-01
KR20100132070A (en) 2010-12-16
RU2501794C2 (en) 2013-12-20
EP3424917A1 (en) 2019-01-09
IL208754A0 (en) 2010-12-30
US20110098480A1 (en) 2011-04-28
JP5474769B2 (en) 2014-04-16
NZ588612A (en) 2012-08-31
WO2009128558A1 (en) 2009-10-22
HUE039145T2 (en) 2018-12-28
BRPI0911197A2 (en) 2015-10-13
ZA201007392B (en) 2012-01-25
CN102083810B (en) 2014-10-29
EP2277874B1 (en) 2018-06-27

Similar Documents

Publication Publication Date Title
DK2277874T3 (en) ACTIVATOR FOR PEROXISOM PROLIFERATOR-ACTIVATED RECEPTOR
JP6049791B2 (en) Activator of peroxisome proliferator activated receptor δ
JP4790969B2 (en) Activator of peroxisome proliferator-responsive receptor δ
JP4157381B2 (en) Activator of peroxisome proliferator-responsive receptor
JP4421895B2 (en) Activator of peroxisome proliferator-responsive receptor δ
JPWO2006059744A1 (en) Activator of peroxisome proliferator activated receptor δ
JPWO2008016175A1 (en) Peroxisome proliferator-activated receptor activator
JPWO2006090920A1 (en) Activator of peroxisome proliferator activated receptor δ
JPWO2007004733A1 (en) Activator of peroxisome proliferator activated receptor δ
JPWO2006041197A1 (en) Activator of peroxisome proliferator activated receptor δ
JPWO2006126714A1 (en) Peroxisome proliferator-activated receptor activator
JP2013006769A (en) Activator for peroxisome proliferator activating receptor
JPH09176163A (en) 2,4-thiazolidinedione or oxazolidinedione derivative and hypoglycemic agent